propranolol has been researched along with Skin Neoplasms in 338 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The initial recommendation propranolol usage in managing infantile hemangioma was in 2008 followed by various researches assessing the dosage, efficacy, and other parameters." | 9.51 | Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma. ( Bessar, H; Kandil, AH; Khattab, F; Nasr, NM, 2022) |
| " Here, we report the results of dose escalation of a nonselective β-blocker (propranolol) with pembrolizumab in patients with metastatic melanoma." | 9.41 | Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. ( Allen, C; Attwood, K; Bucsek, MJ; Cedeno, CD; Drabick, JJ; Ernstoff, MS; Funchain, P; Gandhi, S; Ji, W; Knudsen, ES; Levis, M; Mohammadpour, H; Pandey, MR; Puzanov, I; Repasky, EA; Stack, S; Tario, JD; Wallace, PK; Witkiewicz, AK, 2021) |
| "Topical timolol and lasers are widely used for the treatment of infantile hemangioma (IH), and they can replace propranolol as the first-line treatment of IH." | 9.22 | Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: A meta-analysis of 10 studies. ( Cai, B; Chen, X; Huang, H; Wang, B; Yu, J, 2022) |
| "The combination treatment for mix infantile hemangiomas (IHs) using oral propranolol with topical timolol maleate was not well documented in the literature." | 9.22 | Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. ( Li, G; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2016) |
| "Propranolol has been widely used in the treatment of infantile hemangiomas since 2008." | 9.22 | Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas. ( Chang, L; Chen, H; Hu, L; Huang, H; Jin, Y; Li, W; Lin, X; Ma, G; Qiu, Y; Xu, X; Zhou, B, 2016) |
| "Combining propranolol with corticosteroids gives a faster response and should be considered in treating life- or function-threatening hemangiomas." | 9.20 | Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. ( Abdel Kader, HM; Aly, MM; Ghazy, MS; Hamza, AF; Ragab, IA; Saafan, HA, 2015) |
| "The dramatic response of infantile hemangiomas to propranolol and few side effects suggest that early treatment of infantile hemangiomas could result in decreased disfigurement." | 9.17 | Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas. ( Aozasa, N; Araki, M; Inuzuka, R; Isomura, S; Kagami, S; Katori, T; Kuwano, Y; Masui, Y; Miyagawa, T; Miyamoto, A; Sato, S; Shibata, S; Takahashi, K; Uwajima, Y; Yamada, D; Yamamoto, M, 2013) |
| "To assess propranolol efficacy and safety in complicated infantile hemangiomas in two different age groups." | 9.17 | The use of propranolol for complicated infantile hemangiomas. ( Dalmonte, P; Occella, C; Pelegrini, M; Rimini, A; Romanini, MV; Vercellino, N, 2013) |
| "The purpose of this study was to compare the efficacy of orally administered propranolol versus prednisolone versus both in the treatment of potentially disfiguring or functionally threatening infantile hemangiomas." | 9.17 | Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. ( Malik, MA; Menon, P; Rao, KL; Samujh, R, 2013) |
| "To observe the therapeutic effect of propranolol with 1 064 nm Nd:YAG laser on proliferating hemangioma in body surface." | 9.16 | [The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface]. ( Duan, B; Gong, H; Tan, M; Zhou, CM, 2012) |
| "To evaluate the short-term efficacy and safety of propranolol for problematic infantile hemangiomas." | 9.15 | [Propranolol in the treatment of problematic infantile hemangiomas]. ( Chen, J; Huang, J; Li, S; Lu, J; Qin, G; Tna, L; Xiang, Y; Yang, S; Zhao, J; Zuo, C, 2011) |
| "Propranolol is a well tolerated and effective treatment for infantile hemangiomas." | 8.98 | Infantile hemangiomas: what have we learned from propranolol? ( Ghareeb, E; Hagen, R; Jalali, O; Zinn, Z, 2018) |
| "Propranolol has become the first-line treatment for complicated Infantile Hemangioma (IH), showing so far a good risk-benefit profile." | 8.95 | Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report. ( Cutrone, M; Dalle Carbonare, M; Perilongo, G; Pettenazzo, A; Sartori, S; Tosoni, A, 2017) |
| "Currently, propranolol is the preferred treatment for problematic proliferating infantile haemangiomas (IHs)." | 8.91 | The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. ( Chen, S; Ji, Y; Li, L; Xiang, B; Xu, C, 2015) |
| "The introduction of propranolol as systemic therapy for infantile hemangiomas (IH) has changed the natural history of these tumors." | 8.31 | Propranolol and infantile hemangiomas: Outcome from a tricentric study. ( Benetton, C; Cimador, M; De Corti, F; Gamba, P; Midrio, P; Pace, MD, 2023) |
| "Despite its effectivity, there are reports of poor response to propranolol in the treatment of infantile hemangioma (IH)." | 8.31 | Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it? ( Pandey, A; Pant, N; Rawat, J; Singh, S; Srivastava, A, 2023) |
| "The distribution and response to propranolol of problematic facial infantile haemangiomas (IHs) has rarely been described in the literature." | 8.31 | Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study. ( Chang, L; Chang, SJ; Chen, J; Chen, Q; Gao, W; Li, H; Lin, X; Qiu, Y; Yu, Z; Zhou, L, 2023) |
| "We studied 95 patients with infantile hemangioma (IH) treated with propranolol at the Department of Dermatology, Kumamoto University Hospital, from November 2016 to January 2022, based on sex, site, clinical classification, duration of treatment, and residual lesions after treatment." | 8.31 | A study of 95 infantile hemangiomas treated with propranolol: A potentially efficacious combination with laser therapy. ( Amano, F; Aoi, J; Fukushima, S; Kajihara, I; Makino, K; Masuguchi, S; Nakayama, W; Nishimura, Y; Sawamura, S; Shimada, S; Yamada-Kanazawa, S, 2023) |
| "Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical data on the safety and tolerability of propranolol in neonates are still lacking." | 8.31 | Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population. ( Bai, H; Cheng, J; Fu, R; Huan, X; Huang, M; Jin, P; Wu, Z; Yuan, H; Zou, Y, 2023) |
| "Between January 2016 and February 2019, dermatologists experienced hemangioma treatment and recommended propranolol treatment for 232 IHs." | 8.31 | Our experience with propranolol for infantile hemangioma. ( Dai, T; Lu, W; Song, W; Wang, L; Wu, Y; Zhao, P, 2023) |
| "Propranolol is the first-line treatment for infantile hemangiomas (IH)." | 8.31 | Predictors of poor response to oral propranolol in infantile hemangiomas. ( Berrami, H; Chiheb, S; Hali, F; Moubine, I; Othmani, MB; Serhier, Z, 2023) |
| "To evaluate the safety of initiating and maintaining propranolol therapy for infantile hemangioma (IH) and the safety of different doses." | 8.12 | Safety assessment of propranolol for infantile hemangioma: a study in an Asian population. ( Han, X; He, R; Li, L; Liu, Y; Ma, L; Qiu, L; Sun, Y; Wang, C; Wei, L; Xiu, B; Xu, Z; Yu, L; Zhang, B, 2022) |
| "For infantile hemangiomas (IH) requiring treatment, including those in high-risk locations or in the setting of ulceration, oral propranolol is first-line therapy." | 8.12 | Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol. ( Boull, C; Maguiness, S; Meyer-Mueller, C; Nicholson, C; Polcari, I, 2022) |
| "We report three infants with infantile hemangioma who experienced severe agitation and diarrhea following propranolol administration." | 8.12 | Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects. ( Chen, A; Poffenberger, P; Twist, J; Zinn, Z, 2022) |
| "Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established." | 8.12 | Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. ( Check, JF; Gatts, JE; McLean, TW; Rush, MC; Samelak, DM, 2022) |
| "Propranolol is used as the first-line treatment for infantile hemangiomas (IHs)." | 8.12 | Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream. ( Endoh, A; Hakamata, A; Inui, N; Kashiwagura, Y; Namiki, N; Shirai, M; Tanaka, S; Uchida, S; Watanabe, H, 2022) |
| "To assess the adverse effects of propranolol therapy in infantile hemangioma." | 8.02 | Adverse Drug Reactions Following Propranolol in Infantile Hemangioma. ( Imran, M; Kumar, D; Mishra, A; Pandey, V; Sharma, SP; Tiwari, P, 2021) |
| "Oral propranolol accelerates the involution of infantile haemangiomas (IHs)." | 8.02 | Sequelae following infantile haemangiomas treated with propranolol. ( Baselga, E; Bassi, A; Bernabeu-Wittel, J; Carnevale, C; Diociaiuti, A; Downey, C; El Hachem, M; Gich, I; Gonzalez-Enseñat, MA; Knopfel, N; Leuzzi, M; Manunza, F; Mascaro, P; Monserrat-García, MT; Neri, I; Oranges, T; Ortiz-Prieto, A; Puig, L; Roe, E; Torrelo, A; Vercellino, N; Vicente, A, 2021) |
| "Oral propranolol is the treatment of choice for infantile hemangiomas." | 8.02 | Recurrence rate of infantile hemangioma after oral propranolol therapy. ( Byeon, JO; Frongia, G; Günther, P; Mehrabi, A, 2021) |
| "The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites." | 8.02 | Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas. ( Bi, J; Gao, Q; Huo, R; Li, S; Li, X; Lv, R; Wang, L; Xu, G, 2021) |
| "Propranolol emerged as the first-line therapy for infantile hemangioma (IH)." | 8.02 | Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth. ( Khamaysi, Z; Kridin, K; Pam, N, 2021) |
| "Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function." | 8.02 | Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study. ( Gnannt, R; Kernland-Lang, K; Knöpfel, N; Kohler, M; Kurth, S; Luchsinger, I; Neuhaus, K; Schoch, SF; Schwieger-Briel, A; Smith, A; Theiler, M; von der Heydt, S; Waelchli, R; Weibel, L, 2021) |
| "We present a case of a one-month-old female patient with severe hypertriglyceridaemia as a side effect of treating an ulcerating infantile hemangioma with systemic propranolol." | 8.02 | Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma. ( Farshchian, M; Potts, GA, 2021) |
| "The highest efficacy of oral propranolol is for infantile hemangioma (IH) in the proliferative phase." | 7.96 | Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study. ( Bergman, R; Khamaysi, Z; Kridin, K; Pam, N, 2020) |
| "Oral propranolol (OP) demonstrated high efficacy and safety profile for treatment of critical infantile hemangiomas (IHs)." | 7.96 | A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. ( Caini, M; Cartocci, A; Cevenini, G; Cinotti, E; de Quattro, M; Fiorani, D; Ierardi, F; Oranges, T; Pianigiani, E; Rubegni, P; Tognetti, L, 2020) |
| "We describe a case of a 6-month-old female patient with a segmental, superficial, infantile hemangioma (IH) on the forehead being treated with propranolol 2 mg/kg/d for 5 months, who developed a symplastic hemangioma (SH) over the preexisting lesion, highlighting the need to consider SH in the differential diagnosis of vascular lesions arising over preexisting vascular anomalies in children." | 7.91 | Symplastic hemangioma developing over an infantile hemangioma during propranolol treatment. ( Cervilla, K; Downey, C; González, S; Kramer, D; Pino, G; Zambrano, MJ, 2019) |
| "Propranolol is an effective method of treatment for infantile hemangiomas (IH)." | 7.91 | Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas. ( Babiak-Choroszczak, L; Bagłaj, M; Dawid, G; Gawrych, E; Giżewska-Kacprzak, K, 2019) |
| "Propranolol is the mainstay of treatment for infantile hemangiomas (IHs) benefited from its low complication in the present study." | 7.91 | Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol. ( Guo, L; Li, J; Song, D; Wang, C; Wang, L; Wu, C, 2019) |
| "To present the outcomes of fixed doses of propranolol tablets for the treatment of hemangiomas." | 7.91 | EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT. ( Anger, J; Gabel, J; Oliveira, EM, 2019) |
| "This was a retrospective study to analyze the clinical therapeutic efficacy of propranolol in patients with infantile hemangioma (IH)." | 7.91 | Therapeutic efficacy of propranolol for infantile hemangiomas. ( Chen, Y; Gao, Z; Hao, J; Li, F; Wang, H; Wu, W, 2019) |
| "To study the clinical effectiveness of β-blocker therapy in patients with melanoma and to determine whether propranolol improves progression-free survival in patients with melanoma." | 7.88 | Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. ( Benemei, S; Botteri, E; De Giorgi, V; Gandini, S; Geppetti, P; Grazzini, M; Marchionni, N; Pennacchioli, E, 2018) |
| "There has been a paradigm shift from steroids to propranolol for the pharmacologic treatment of infantile hemangiomas (IH); however, the outcomes for ulcerated IH are not well studied." | 7.88 | Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas. ( Chute, C; Dasgupta, R; Hammill, A; Polites, SF; Rodrigue, BB, 2018) |
| "Treating infantile haemangioma with propranolol is more cost-effective when initiated on an outpatient basis." | 7.88 | Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting. ( Chaturvedi, K; Snyder, CS; Steinberg, JS, 2018) |
| "Propranolol is the treatment of choicefor complicated infantile hemangiomas (IH)." | 7.85 | Propranolol for infantile hemangiomas in developing countries. ( Lawley, LP; McMichael, J, 2017) |
| "Despite not being licensed for the treatment of infantile hemangiomas (IH) in infants younger than 5 weeks or older than 5 months, propranolol is often used in these age groups to prevent or to treat potentially severe complications." | 7.85 | Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience. ( Berti, I; Boccaletti, V; Carnevale, C; Cutrone, M; Dalmonte, P; Diociaiuti, A; El Hachem, M; Gesualdo, F; Greco, A; Neri, I; Oranges, T; Porcedda, G; Vercellino, N, 2017) |
| "Propranolol hydrochloride has become the primary medical treatment for problematic infantile hemangioma; however, the expression of propranolol's target receptors during growth, involution, and treatment of hemangioma remains unclear." | 7.85 | Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas. ( Phillips, JD; Richter, GT; Wei, T; Zhang, H, 2017) |
| "Oral propranolol has been recently approved for infantile hemangiomas (IHs), but potential side effects stay a challenge." | 7.85 | Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. ( Parezanović, V; Petrovic, J; Topalovic, M; Trajkovic, G; Trifunovic, B; Vukomanovic, G, 2017) |
| "Concern has been raised about the potential long-term effects of propranolol treatment for infantile hemangioma (IH)." | 7.85 | Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age. ( Moyakine, AV; Spillekom-van Koulil, S; van der Vleuten, CJM, 2017) |
| "The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants." | 7.83 | Efficacy of propranolol for cutaneous hemangiomas in premature children. ( Barruscotti, S; Borroni, G; Brazzelli, V; Codazzi, CA; Giorgini, C; Mannarino, S; Marseglia, GL; Stronati, M; Tzialla, C, 2016) |
| "A retrospective observational study was conducted on patients with ulcerated infantile haemangioma treated with pulsed dye laser in association with propranolol." | 7.83 | [Combination of pulsed dye laser and propranolol in the treatment of ulcerated infantile haemangioma]. ( del Pozo Losada, J; Rodríguez-Ruiz, M; Tellado, MG, 2016) |
| "Oral propranolol is widely prescribed as first-line treatment for infantile haemangiomas (IHs)." | 7.83 | Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. ( Audrain, H; Baryschpolec, S; Baselga, E; Beattie, PE; Bhate, K; Bjerre, JV; Brown, SJ; Burrows, NP; Clayton, TH; Darne, S; Durack, A; Dvorakova, V; Flohr, C; Foelster-Holst, R; Gach, J; Glover, M; Goldstraw, N; Goodyear, H; Grabczynska, S; Greenblatt, D; Halpern, J; Hearn, RM; Hedelund, L; Hernandez-Martin, A; Hoeger, PH; Hoey, S; Hughes, B; Irvine, AD; Janmohamed, SR; Jayaraj, R; Johansson, EK; Laguda, B; Lam, M; Leech, S; McPherson, T; Morrison, D; Neri, I; O'Regan, GM; Oranje, AP; Patrizi, A; Porter, W; Ramesh, R; Ravenscroft, JC; Schill, T; Shahidullah, H; Shaw, L; Solman, L; Svensson, A; Taylor, AE; Taylor, R; Thomson, J; Tiffin, P; Tsakok, M; Wahlgren, CF; Wedgeworth, E, 2016) |
| "The aim of this study was to explore the efficacy and safety of propranolol in treating infantile haemangiomas, the most common benign vascular tumours in children." | 7.83 | Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. ( Jetsrisuparb, C; Komwilaisak, P; Panombualert, S; Techasatian, L; Uppala, R, 2016) |
| "From October 2010 to June 2014, 31 infantile hemangioma patients admitted to our hospital, were administered propranolol combined with betamethasone injection treatment of lesions." | 7.83 | Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone. ( Li, J; Shao, RZ; Zhao, DH, 2016) |
| " The medical records of infants with periorbital hemangiomas who were treated with systemic propranolol at a dose of 1." | 7.83 | Clinical Outcomes of Infants With Periorbital Hemangiomas Treated With Oral Propranolol. ( Liu, ZM; Sun, C; Wang, XK; Xu, DP; Xue, L, 2016) |
| "Propranolol, 2 mg/kg/day, is effective in the treatment of infantile hemangioma." | 7.83 | Response to propranolol in infantile hemangioma. ( Chunharas, A; Kadegasem, P; Lekanan, W; Sirachainan, N; Thammagasorn, Y; Wanitkun, S, 2016) |
| "An open observational prospective study was performed over 25 months in a group of pediatric patients diagnosed with infantile hemangioma treated with propranolol." | 7.83 | The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol. ( Castaneda, S; De la Cruz, H; Garcia, E; Melendez-Lopez, S; Sanchez-Palacio, J, 2016) |
| "There has been a dramatic increase in the off-label use of ophthalmic timolol maleate, a β-blocker used for infantile hemangioma (IH) treatment as a topical counterpart to oral propranolol." | 7.83 | Topical Timolol Maleate Treatment of Infantile Hemangiomas. ( Adams, D; Baselga, E; Drolet, B; Feigenbaum, D; Frieden, I; Garzon, MC; Holland, K; Horii, K; Lauren, C; Lucky, A; Mathes, E; McCuaig, C; Morel, KD; Newell, B; Nopper, A; Pope, E; Powell, J; Püttgen, K; Savva, Y; Siegel, D; Song, W, 2016) |
| "In recent years propranolol has become the treatment of choice for infantile hemangiomas (IHs)." | 7.83 | Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas? ( Krol, AL; Leitenberger, SL; MacArthur, CJ; Mann, JA; Tollefson, MM; Yarbrough, KB, 2016) |
| "Non-selective β-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response." | 7.83 | [Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Jiang, CH; Lei, SR; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016) |
| "Although propranolol has been accepted as a first-line drug for infantile haemangioma (IH), no study has systematically characterized changes in heart rates during long-term propranolol treatment." | 7.81 | Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment. ( Chen, W; Shi, H; Song, H; Wang, J; Yu, Y; Zhang, X; Zhou, H, 2015) |
| "Propranolol has been recently approved by health authorities to treat infantile haemangiomas (IH)." | 7.81 | [Propranolol in infantile hemangiomas]. ( Léauté-Labrèze, C, 2015) |
| "Topical propranolol has been used for the therapy of superficial infantile hemangiomas (IH)." | 7.81 | A novel topical nano-propranolol for treatment of infantile hemangiomas. ( Chen, ZG; Yuan, ML; Yuan, WE; Zhang, L; Zheng, JW, 2015) |
| "This study suggests that propranolol become the first-line treatment of choice for all haemangiomas." | 7.81 | Shouldn't Propranolol Be Used to Treat All Haemangiomas? ( Adams, KG; Adams, S; Hudson, DA; Moodley, ST, 2015) |
| "Our aim was to compare in a prospective study the clinical effects and safety of propranolol given orally, timolol maleate applied locally, and the combination of the two, in the management of superficial infantile haemangiomas." | 7.81 | Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. ( Cheng, C; Gong, H; Li, G; Li, YX; Wang, XK; Xu, DP, 2015) |
| "To explore the effect and safety of topical propranolol hydrochloride gel for treatment of infantile hemangioma." | 7.81 | [Effects of topical propranolol hydrochloride gel for treatment of infantile hemangioma in nude mice]. ( Chen, L; Chengjin, L; Lie, W; Qingjin, H; Shaoquan, C; Shuming, C; Yin, X; Zaizhong, Z, 2015) |
| "Propranolol is emerging as the treatment of choice for high-risk infantile haemangiomas." | 7.80 | Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure. ( McSwiney, E; Murphy, M; Murray, D, 2014) |
| "This study proved high efficiency of propranolol in treatment of infantile hemangioma, as assessed with the objective measures for the first time." | 7.80 | Treatment of infantile hemangiomas with propranolol: clinical guidelines. ( Anderson, W; Stewart, K; Szychta, P, 2014) |
| "Propranolol is highly effective in the treatment of infantile hemangioma (IH), but important clinical and pharmacological data are lacking." | 7.80 | Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. ( Ben Amitai, D; Lapidoth, M; Sagi, L; Zvulunov, A, 2014) |
| "A small percentage of complicated infantile haemangiomas need early, safe and effective treatment, and the option of off-label systemic propranolol treatment has been in existence since 2008." | 7.80 | A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. ( Cremer, HJ; Ruef, P; Schneider, M, 2014) |
| "To assess the safety and efficacy of systemic propranolol for the treatment of complicated infantile haemangiomas." | 7.80 | Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. ( Glover, M; Gnarra, M; Harper, JI; Murabit, A; Solman, L; Syed, SB, 2014) |
| "This study was aimed at assessing the efficacy of propranolol treatment in infantile hemangiomas (IHs) by ultrasound." | 7.80 | Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. ( Shang, Y; Shi, H; Song, H; Wang, J; Xia, L; Yang, J; Zhou, H, 2014) |
| "Infantile hemangioma (IH) clearance may be slow or incomplete in response to pulsed dye laser (PDL) or propranolol alone." | 7.79 | Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser. ( Anolik, R; Bernstein, L; Blei, F; Brauer, JA; Brightman, L; Geronemus, RG; Hale, E; Karen, J; Reddy, KK; Waner, M; Weiss, E, 2013) |
| "Propranolol has been used successfully in a limited number of children with infantile hemangiomas (IHs)." | 7.79 | Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region. ( Kasimova, KR; Metellmann, HR; Podmelle, F; Sadykov, RA; Sadykov, RR, 2013) |
| "Propranolol is now widely used to treat severe infantile haemangiomas (IHs)." | 7.79 | Propranolol-resistant infantile haemangiomas. ( Aubert, H; Barbarot, S; Boccara, O; Bursztejn, AC; Caussé, S; Chiaverini, C; Dreyfus, I; Eschard, C; Hadj-Rabia, S; Mahé, E; Maruani, A; Mazereeuw-Hautier, J; Miquel, J; Puzenat, E; Saint-Jean, M; Stalder, JF, 2013) |
| "Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment." | 7.79 | Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. ( Ahogo, CK; Boralevi, F; Colona, V; Diallo, A; Ezzedine, K; Léauté-Labrèze, C; Prey, S; Taïeb, A, 2013) |
| "To evaluate the efficacy and safety of 1% propranolol ointment in the treatment of superficial infantile hemangiomas (IHs)." | 7.79 | [Treatment of superficial infantile hemangiomas with topical propranolol]. ( Huo, R; Lü, RR; Niu, JN; Xu, GQ, 2013) |
| "We sought to determine the effect of propranolol on cardiovascular and blood glucose parameters in infants with symptomatic infantile hemangiomas who were hospitalized for initiation of treatment, and to analyze adverse effects of propranolol throughout the course of inpatient and outpatient treatment." | 7.79 | Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. ( Bauman, NM; Boss, EF; Cohen, BA; Puttgen, KB; Schneider, J; Summerer, B, 2013) |
| "Propranolol was recently discovered to be an effective treatment for infantile haemangiomas, and varying doses and monitoring regimens have been proposed." | 7.78 | Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis. ( Dyme, JL; Han, EJ; Kotb, ME; Nyirenda, TL; Shin, HT; Thampan, A, 2012) |
| "A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication." | 7.78 | Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding? ( Buffon, RB; Cavalli, R; Colli, AM; de Souza, M; Gelmetti, C, 2012) |
| "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)." | 7.78 | Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012) |
| "To evaluate changes in infantile hemangioma tissue before and after propranolol therapy, using gray-scale and color Doppler ultrasound imaging." | 7.78 | Propranolol reduces infantile hemangioma volume and vessel density. ( Bingham, MM; Perkins, JA; Saltzman, B; Vo, NJ, 2012) |
| " To evaluate the effectiveness, safety and tolerability of propranolol as single-agent treatment in patients with problematic, proliferative-phase, infantile hemangiomas (IHs)." | 7.78 | Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience. ( Georgountzou, A; Kakourou, T; Karavitakis, E; Klimentopoulou, A; Xaidara, A, 2012) |
| "Propranolol has recently emerged as an effective drug treatment for infantile haemangiomas." | 7.78 | Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. ( Bekhor, PS; Crock, CM; Penington, AJ; Phillips, RJ, 2012) |
| "Discuss effect and dynamics of propranolol (PR) treatment in infantile haemangioma (IH) of head and neck in children during follow-up." | 7.78 | Propranolol for infantile haemangioma: striking effect in the first weeks. ( Csákányi, Z; Gács, E; Gerlinger, I; Katona, G; Ráth, G; Szalai, Z, 2012) |
| "We report here the case of an infant with multiple hepatic and cutaneous infantile hemangiomas (IHs) associated with deranged liver function who was treated successfully with low-dose propranolol." | 7.77 | Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011) |
| "Recent reports have described the successful use of propranolol to treat severe hemangiomas of infancy." | 7.77 | [Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients]. ( Bernabeu-Wittel, J; Conejo-Mir, J; de Agustín, JC; Fernández-Pineda, I; Mantrana-Bermejo, ME; Pereyra-Rodríguez, JJ, 2011) |
| "Four children with haemangiomas of the head and neck were treated with propranolol at a tertiary referral centre." | 7.77 | Failure of propranolol in the treatment of childhood haemangiomas of the head and neck. ( Bruce, IA; Goswamy, J; Rothera, MP, 2011) |
| "We report the rapid and dramatic efficacy of propranolol in 8 infants with infantile hepatic hemangiomas." | 7.76 | Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. ( Ammour, A; Benlahrech, S; Bodemer, C; Broue, P; Hoeger, PH; Labenne, M; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Ohanessian, G; Rössler, J; Vabres, P; Vial, J, 2010) |
| " She was given propranolol after her tracheotomy and had a significant reduction in her subglottic airway obstruction." | 7.76 | Propranolol in the management of airway infantile hemangiomas. ( Frieden, IJ; Maguiness, SM; Meyer, AK; Rosbe, KW; Suh, KY, 2010) |
| "Propranolol treatment was recently reported to be successful for the management of severe infantile hemangioma." | 7.76 | Hyperkalemia complicating propranolol treatment of an infantile hemangioma. ( Kietz, S; Lakomek, M; Lauerer, P; Pavlakovic, H; Zutt, M, 2010) |
| "There are recent reports of effective treatment of cutaneous hemangiomas with Propranolol." | 7.75 | Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. ( Denoyelle, F; Enjolras, O; Garabedian, EN; Harris, R; Leboulanger, N; Roger, G, 2009) |
| " Our study suggested that oral propranolol combined with topical timolol treatment is very effective and well-tolerated for compound IHs, which can be used as a first line treatment." | 6.82 | Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. ( Ge, J; Yuan, W; Zhang, L; Zhao, H; Zheng, J, 2016) |
| "Propranolol treatment decreases urinary excretion of MMP-9 in patients with IH." | 6.78 | Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. ( Bauman, N; Brown, KJ; Movius, E; Preciado, D; Saieg, A; Thaivalappil, S, 2013) |
| "Infantile haemangioma is the commonest childhood tumour and approximately 10% requires treatment." | 6.76 | Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. ( Gorst, C; Holmes, WJ; Liew, SH; Mishra, A, 2011) |
| "Infantile haemangiomas are the most common tumour of infancy." | 6.58 | Topical propranolol for infantile haemangiomas: a systematic review. ( Birchall, JC; Elhassan, HA; Mcleod, RWJ; Price, A; Rai, S, 2018) |
| "Propranolol treatment mostly leads to regression of hemangiomas with satisfactory aesthetic results, but unfortunately not in all cases." | 5.91 | Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment. ( Avitan-Hersh, E; Khamaysi, Z; Pam, N; Zaaroura, H, 2023) |
| " To evaluate the correlation of clinical features between cutaneous IH and IHH, as well as efficacy of systemic propranolol in the treatment of cutaneous IH combined with IHH." | 5.91 | Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment. ( Han, X; Li, L; Ma, L; Sun, Y; Wei, L; Xu, Z; Yu, L; Zhang, B, 2023) |
| "Oral propranolol has not been shown to impact physical development, such as weight and height." | 5.91 | The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment. ( Chen, S; Chen, X; Deng, L; Gao, J; Huang, L; Lin, X; Liu, C; Wang, Q; Wang, T, 2023) |
| "Propranolol was successfully tapered over 3 weeks by reducing the dose by 50% weekly until it reached the therapeutic dose." | 5.91 | Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report. ( Alessa, A; Alghanem, A; Alhammad, AM; Alshammari, H; Elsharawy, Y, 2023) |
| " Adverse event and drug-related adverse event rates were 87." | 5.72 | Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study. ( Hakamata, A; Hayano, S; Inui, N; Iwashima, S; Kashiwagura, Y; Nagata, E; Nishida, M; Odagiri, K; Okada, E; Sano, S; Tanaka, S; Uchida, S; Umemura, K; Watanabe, H, 2022) |
| "Propranolol is a safe, effective and well-tolerated treatment in Australian children with IH." | 5.72 | Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019. ( Adams, L; Ryan, E, 2022) |
| "Severe hypoglycemia was common in infants aged >1 year, when PPL was used for ≥6 months." | 5.72 | Severe hypoglycemia in propranolol treatment for infantile hemangiomas. ( Baba, N; Kaneko, T; Kuwano, Y; Morimoto, A; Ozeki, M; Sasaki, S, 2022) |
| "Oral propranolol has been well established as the first-line treatment of complicated hemangiomas; however, variability in the administration protocol remains." | 5.62 | Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol. ( Johansen, ML; Lawley, LP; Mahendran, G, 2021) |
| " Although oral propranolol is currently first-line therapy, optimal dosing for treatment of IH remains debated." | 5.56 | Retrospective case series of increased oral propranolol dosage for infantile hemangiomas. ( Aggarwal, P; Cohen, BA; Huang, AH; Mahon, M; Mannschreck, D, 2020) |
| "The initial recommendation propranolol usage in managing infantile hemangioma was in 2008 followed by various researches assessing the dosage, efficacy, and other parameters." | 5.51 | Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma. ( Bessar, H; Kandil, AH; Khattab, F; Nasr, NM, 2022) |
| "Infantile hemangiomas are the most common tumor of childhood and undergo rapid growth during early infancy followed by gradual involution." | 5.48 | Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. ( Kagami, S; Kaneko, M; Katori, T; Kishi, A, 2018) |
| "The propranolol treatment for the patient with suspected of bronchial asthma was suspended for 4 months." | 5.48 | Oral propranolol for infantile hemangiomas beyond the proliferative phase. ( Kagami, S; Katori, T, 2018) |
| " The dosage of propranolol was increased from 0." | 5.46 | Successful Treatment of Infantile Hemangiomas With Propranolol in Low-Birth-Weight Infants. ( Hayashi, A; Kado, M; Matsumura, T; Mizuno, H; Mochizuki, M; Shimizu, A, 2017) |
| "Hemangiomas are common skin lesion, affecting 10-12% of children <1year of age." | 5.43 | The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser. ( Dementieva, N; Jones, S, 2016) |
| "Oral propranolol was successful in 95." | 5.43 | Propranolol treatment for infantile hemangioma: a case series of sixty-two patients. ( Barbato, G; Boccaletti, V; Carano, N; Cerasoli, G; Gritti, A; Lombardi, AA; Marchesi, M; Stringari, G; Tchana, B; Zanzucchi, M, 2016) |
| " However, the appropriate drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects remains controversial." | 5.43 | [Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Li, K; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016) |
| "Infantile hemangiomas are the most common vascular tumors in childhood." | 5.42 | Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report. ( del Boz González, J; Navarro Morón, J; Porcel Chacón, R, 2015) |
| " Here, we report the results of dose escalation of a nonselective β-blocker (propranolol) with pembrolizumab in patients with metastatic melanoma." | 5.41 | Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. ( Allen, C; Attwood, K; Bucsek, MJ; Cedeno, CD; Drabick, JJ; Ernstoff, MS; Funchain, P; Gandhi, S; Ji, W; Knudsen, ES; Levis, M; Mohammadpour, H; Pandey, MR; Puzanov, I; Repasky, EA; Stack, S; Tario, JD; Wallace, PK; Witkiewicz, AK, 2021) |
| " The most important adverse effects were hypotension (3·4%), wheezing (9·2%), nocturnal restlessness (22·4%) and cold extremities (36·2%)." | 5.39 | Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. ( Bauland, CG; Hermans, DJ; van Beynum, IM; van der Vleuten, CJ; Zweegers, J, 2013) |
| "Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3." | 5.37 | Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. ( Hermans, DJ; Schultze Kool, LJ; van Beynum, IM; van de Kerkhof, PC; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH." | 5.37 | Propranolol for treatment of ulcerated infantile hemangiomas. ( Barbarot, S; Bodak, N; Hadj-Rabia, S; Hamel-Teillac, D; Kupfer-Bessaguet, I; Lacour, JP; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Naouri, M; Nguyen, JM; Saint-Jean, M; Stalder, JF; Vabres, P, 2011) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor in children." | 5.37 | Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. ( de Blaauw, I; Hermans, DJ; Kool, LJ; van Beynum, IM; van der Vijver, RJ; van der Vleuten, CJ, 2011) |
| "Propranolol appears to be an effective treatment option for IH even in the nonproliferative phase and after the first year of life." | 5.37 | Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. ( Breugem, CC; Breur, JMPJ; de Graaf, M; Pasmans, SGMA; Raphaël, MF; Vos, M, 2011) |
| "PHACE syndrome is a neurocutaneous disorder with large facial segmental hemangionas associated with anomalies of the brain, eye, heart and aorta." | 5.37 | Use of propranolol for treatment of hemangiomas in PHACE syndrome. ( Deming, D; Hopper, A; Merritt, TA; Ninnis, J; Solomon, T, 2011) |
| "Oral propranolol was given for a period of 6 months with monthly follow up." | 5.37 | Initial experiences with propranolol treatment of infantile hemangiomas: report of three cases. ( Halilbasic, A; Halilbasic, M; Hotic, N; Husaric, E; Husaric, S; Rahmanovic, E, 2011) |
| "Propranolol was given to 32 children (21 girls; mean age at onset of treatment: 4." | 5.35 | Propranolol for severe infantile hemangiomas: follow-up report. ( Berge, J; Boralevi, F; de la Roque, ED; Dupuis, E; Ezzedine, K; Grenier, N; Léauté-Labrèze, C; Lipsker, D; Mazereeuw-Hautier, J; Sans, V; Taïeb, A; Vergnes, P, 2009) |
| "Hemangioma is the most common tumor of infancy." | 5.35 | [Response to oral propranolol therapy for ulcerated hemangiomas in infancy]. ( Michel, JL; Patural, H, 2009) |
| "Topical timolol and lasers are widely used for the treatment of infantile hemangioma (IH), and they can replace propranolol as the first-line treatment of IH." | 5.22 | Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: A meta-analysis of 10 studies. ( Cai, B; Chen, X; Huang, H; Wang, B; Yu, J, 2022) |
| "The combination treatment for mix infantile hemangiomas (IHs) using oral propranolol with topical timolol maleate was not well documented in the literature." | 5.22 | Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. ( Li, G; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2016) |
| "Propranolol has been widely used in the treatment of infantile hemangiomas since 2008." | 5.22 | Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas. ( Chang, L; Chen, H; Hu, L; Huang, H; Jin, Y; Li, W; Lin, X; Ma, G; Qiu, Y; Xu, X; Zhou, B, 2016) |
| "Combining propranolol with corticosteroids gives a faster response and should be considered in treating life- or function-threatening hemangiomas." | 5.20 | Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. ( Abdel Kader, HM; Aly, MM; Ghazy, MS; Hamza, AF; Ragab, IA; Saafan, HA, 2015) |
| "The dramatic response of infantile hemangiomas to propranolol and few side effects suggest that early treatment of infantile hemangiomas could result in decreased disfigurement." | 5.17 | Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas. ( Aozasa, N; Araki, M; Inuzuka, R; Isomura, S; Kagami, S; Katori, T; Kuwano, Y; Masui, Y; Miyagawa, T; Miyamoto, A; Sato, S; Shibata, S; Takahashi, K; Uwajima, Y; Yamada, D; Yamamoto, M, 2013) |
| "To assess propranolol efficacy and safety in complicated infantile hemangiomas in two different age groups." | 5.17 | The use of propranolol for complicated infantile hemangiomas. ( Dalmonte, P; Occella, C; Pelegrini, M; Rimini, A; Romanini, MV; Vercellino, N, 2013) |
| "The purpose of this study was to compare the efficacy of orally administered propranolol versus prednisolone versus both in the treatment of potentially disfiguring or functionally threatening infantile hemangiomas." | 5.17 | Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. ( Malik, MA; Menon, P; Rao, KL; Samujh, R, 2013) |
| "To observe the therapeutic effect of propranolol with 1 064 nm Nd:YAG laser on proliferating hemangioma in body surface." | 5.16 | [The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface]. ( Duan, B; Gong, H; Tan, M; Zhou, CM, 2012) |
| "To evaluate the short-term efficacy and safety of propranolol for problematic infantile hemangiomas." | 5.15 | [Propranolol in the treatment of problematic infantile hemangiomas]. ( Chen, J; Huang, J; Li, S; Lu, J; Qin, G; Tna, L; Xiang, Y; Yang, S; Zhao, J; Zuo, C, 2011) |
| "Propranolol is a well tolerated and effective treatment for infantile hemangiomas." | 4.98 | Infantile hemangiomas: what have we learned from propranolol? ( Ghareeb, E; Hagen, R; Jalali, O; Zinn, Z, 2018) |
| "Propranolol has become the first-line treatment for complicated Infantile Hemangioma (IH), showing so far a good risk-benefit profile." | 4.95 | Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report. ( Cutrone, M; Dalle Carbonare, M; Perilongo, G; Pettenazzo, A; Sartori, S; Tosoni, A, 2017) |
| "Currently, propranolol is the preferred treatment for problematic proliferating infantile haemangiomas (IHs)." | 4.91 | The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. ( Chen, S; Ji, Y; Li, L; Xiang, B; Xu, C, 2015) |
| "Propranolol has been recently adopted as the first-line medical treatment for complicated infantile hemangiomas." | 4.91 | Current trends in medical management of infantile hemangioma. ( Ames, JA; Sykes, JM, 2015) |
| "Propranolol has replaced corticosteroids as preferred first-line therapy for the management of infantile hemangiomas (IH)." | 4.90 | Diagnosis and management of infantile hemangiomas. ( Püttgen, KB, 2014) |
| "The introduction of propranolol as systemic therapy for infantile hemangiomas (IH) has changed the natural history of these tumors." | 4.31 | Propranolol and infantile hemangiomas: Outcome from a tricentric study. ( Benetton, C; Cimador, M; De Corti, F; Gamba, P; Midrio, P; Pace, MD, 2023) |
| "Despite its effectivity, there are reports of poor response to propranolol in the treatment of infantile hemangioma (IH)." | 4.31 | Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it? ( Pandey, A; Pant, N; Rawat, J; Singh, S; Srivastava, A, 2023) |
| "The distribution and response to propranolol of problematic facial infantile haemangiomas (IHs) has rarely been described in the literature." | 4.31 | Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study. ( Chang, L; Chang, SJ; Chen, J; Chen, Q; Gao, W; Li, H; Lin, X; Qiu, Y; Yu, Z; Zhou, L, 2023) |
| "We studied 95 patients with infantile hemangioma (IH) treated with propranolol at the Department of Dermatology, Kumamoto University Hospital, from November 2016 to January 2022, based on sex, site, clinical classification, duration of treatment, and residual lesions after treatment." | 4.31 | A study of 95 infantile hemangiomas treated with propranolol: A potentially efficacious combination with laser therapy. ( Amano, F; Aoi, J; Fukushima, S; Kajihara, I; Makino, K; Masuguchi, S; Nakayama, W; Nishimura, Y; Sawamura, S; Shimada, S; Yamada-Kanazawa, S, 2023) |
| "This study aims to review how the introduction of propranolol as the primary treatment option for children with infantile hemangiomas (IHs) has affected the use of other treatment options at our institution and to determine the indications for surgical treatment of children with IHs in the propranolol era." | 4.31 | Indications for surgical resection of complicated infantile hemangiomas in the β-blocker's era: a single-institution experience from a retrospective cohort study. ( Beqo, BP; Flucher, C; Gasparella, P; Haxhija, EQ; Quehenberger, F; Spendel, S, 2023) |
| "Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical data on the safety and tolerability of propranolol in neonates are still lacking." | 4.31 | Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population. ( Bai, H; Cheng, J; Fu, R; Huan, X; Huang, M; Jin, P; Wu, Z; Yuan, H; Zou, Y, 2023) |
| "Between January 2016 and February 2019, dermatologists experienced hemangioma treatment and recommended propranolol treatment for 232 IHs." | 4.31 | Our experience with propranolol for infantile hemangioma. ( Dai, T; Lu, W; Song, W; Wang, L; Wu, Y; Zhao, P, 2023) |
| "Propranolol is the first-line treatment for infantile hemangiomas (IH)." | 4.31 | Predictors of poor response to oral propranolol in infantile hemangiomas. ( Berrami, H; Chiheb, S; Hali, F; Moubine, I; Othmani, MB; Serhier, Z, 2023) |
| "To evaluate the safety of initiating and maintaining propranolol therapy for infantile hemangioma (IH) and the safety of different doses." | 4.12 | Safety assessment of propranolol for infantile hemangioma: a study in an Asian population. ( Han, X; He, R; Li, L; Liu, Y; Ma, L; Qiu, L; Sun, Y; Wang, C; Wei, L; Xiu, B; Xu, Z; Yu, L; Zhang, B, 2022) |
| "For infantile hemangiomas (IH) requiring treatment, including those in high-risk locations or in the setting of ulceration, oral propranolol is first-line therapy." | 4.12 | Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol. ( Boull, C; Maguiness, S; Meyer-Mueller, C; Nicholson, C; Polcari, I, 2022) |
| "We report three infants with infantile hemangioma who experienced severe agitation and diarrhea following propranolol administration." | 4.12 | Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects. ( Chen, A; Poffenberger, P; Twist, J; Zinn, Z, 2022) |
| "Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established." | 4.12 | Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. ( Check, JF; Gatts, JE; McLean, TW; Rush, MC; Samelak, DM, 2022) |
| "Propranolol is used as the first-line treatment for infantile hemangiomas (IHs)." | 4.12 | Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream. ( Endoh, A; Hakamata, A; Inui, N; Kashiwagura, Y; Namiki, N; Shirai, M; Tanaka, S; Uchida, S; Watanabe, H, 2022) |
| "To assess the adverse effects of propranolol therapy in infantile hemangioma." | 4.02 | Adverse Drug Reactions Following Propranolol in Infantile Hemangioma. ( Imran, M; Kumar, D; Mishra, A; Pandey, V; Sharma, SP; Tiwari, P, 2021) |
| "Oral propranolol accelerates the involution of infantile haemangiomas (IHs)." | 4.02 | Sequelae following infantile haemangiomas treated with propranolol. ( Baselga, E; Bassi, A; Bernabeu-Wittel, J; Carnevale, C; Diociaiuti, A; Downey, C; El Hachem, M; Gich, I; Gonzalez-Enseñat, MA; Knopfel, N; Leuzzi, M; Manunza, F; Mascaro, P; Monserrat-García, MT; Neri, I; Oranges, T; Ortiz-Prieto, A; Puig, L; Roe, E; Torrelo, A; Vercellino, N; Vicente, A, 2021) |
| "Oral propranolol is the treatment of choice for infantile hemangiomas." | 4.02 | Recurrence rate of infantile hemangioma after oral propranolol therapy. ( Byeon, JO; Frongia, G; Günther, P; Mehrabi, A, 2021) |
| "The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites." | 4.02 | Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas. ( Bi, J; Gao, Q; Huo, R; Li, S; Li, X; Lv, R; Wang, L; Xu, G, 2021) |
| "Propranolol emerged as the first-line therapy for infantile hemangioma (IH)." | 4.02 | Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth. ( Khamaysi, Z; Kridin, K; Pam, N, 2021) |
| "Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function." | 4.02 | Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study. ( Gnannt, R; Kernland-Lang, K; Knöpfel, N; Kohler, M; Kurth, S; Luchsinger, I; Neuhaus, K; Schoch, SF; Schwieger-Briel, A; Smith, A; Theiler, M; von der Heydt, S; Waelchli, R; Weibel, L, 2021) |
| "We present a case of a one-month-old female patient with severe hypertriglyceridaemia as a side effect of treating an ulcerating infantile hemangioma with systemic propranolol." | 4.02 | Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma. ( Farshchian, M; Potts, GA, 2021) |
| "Since the discovery of propranolol in the treatment of infantile hemangioma (IH), there has been emergent investigation of β-adrenergic receptor (β-AR) signaling in IH and the mechanisms of action for which β-AR blockers regulate hemangioma cell proliferation." | 3.96 | Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol. ( Knöpfel, N; Oesch, V; Szello, P; Theiler, M; Weibel, L, 2020) |
| "Propranolol is approved for treatment of infantile hemangiomas (IH)." | 3.96 | Special management considerations for propranolol use in breastfed infants of mothers taking antihypertensives. ( Aizman, L; Kirkorian, AY; Krishnan, A; Tender, J; Van Den Anker, J, 2020) |
| "The highest efficacy of oral propranolol is for infantile hemangioma (IH) in the proliferative phase." | 3.96 | Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study. ( Bergman, R; Khamaysi, Z; Kridin, K; Pam, N, 2020) |
| "Oral propranolol (OP) demonstrated high efficacy and safety profile for treatment of critical infantile hemangiomas (IHs)." | 3.96 | A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. ( Caini, M; Cartocci, A; Cevenini, G; Cinotti, E; de Quattro, M; Fiorani, D; Ierardi, F; Oranges, T; Pianigiani, E; Rubegni, P; Tognetti, L, 2020) |
| "We describe a case of a 6-month-old female patient with a segmental, superficial, infantile hemangioma (IH) on the forehead being treated with propranolol 2 mg/kg/d for 5 months, who developed a symplastic hemangioma (SH) over the preexisting lesion, highlighting the need to consider SH in the differential diagnosis of vascular lesions arising over preexisting vascular anomalies in children." | 3.91 | Symplastic hemangioma developing over an infantile hemangioma during propranolol treatment. ( Cervilla, K; Downey, C; González, S; Kramer, D; Pino, G; Zambrano, MJ, 2019) |
| "Propranolol is an effective method of treatment for infantile hemangiomas (IH)." | 3.91 | Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas. ( Babiak-Choroszczak, L; Bagłaj, M; Dawid, G; Gawrych, E; Giżewska-Kacprzak, K, 2019) |
| "Propranolol is the mainstay of treatment for infantile hemangiomas (IHs) benefited from its low complication in the present study." | 3.91 | Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol. ( Guo, L; Li, J; Song, D; Wang, C; Wang, L; Wu, C, 2019) |
| "To present the outcomes of fixed doses of propranolol tablets for the treatment of hemangiomas." | 3.91 | EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT. ( Anger, J; Gabel, J; Oliveira, EM, 2019) |
| "This was a retrospective study to analyze the clinical therapeutic efficacy of propranolol in patients with infantile hemangioma (IH)." | 3.91 | Therapeutic efficacy of propranolol for infantile hemangiomas. ( Chen, Y; Gao, Z; Hao, J; Li, F; Wang, H; Wu, W, 2019) |
| "To study the clinical effectiveness of β-blocker therapy in patients with melanoma and to determine whether propranolol improves progression-free survival in patients with melanoma." | 3.88 | Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study. ( Benemei, S; Botteri, E; De Giorgi, V; Gandini, S; Geppetti, P; Grazzini, M; Marchionni, N; Pennacchioli, E, 2018) |
| "There has been a paradigm shift from steroids to propranolol for the pharmacologic treatment of infantile hemangiomas (IH); however, the outcomes for ulcerated IH are not well studied." | 3.88 | Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas. ( Chute, C; Dasgupta, R; Hammill, A; Polites, SF; Rodrigue, BB, 2018) |
| "Treating infantile haemangioma with propranolol is more cost-effective when initiated on an outpatient basis." | 3.88 | Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting. ( Chaturvedi, K; Snyder, CS; Steinberg, JS, 2018) |
| "Propranolol is the first-line drug for treatment of infantile hemangioma." | 3.88 | Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma. ( An, W; Li, S; Sun, C; Wang, W; Xu, W; Yang, X; Yu, F; Zhang, Y, 2018) |
| "Propranolol is the treatment of choicefor complicated infantile hemangiomas (IH)." | 3.85 | Propranolol for infantile hemangiomas in developing countries. ( Lawley, LP; McMichael, J, 2017) |
| "Despite not being licensed for the treatment of infantile hemangiomas (IH) in infants younger than 5 weeks or older than 5 months, propranolol is often used in these age groups to prevent or to treat potentially severe complications." | 3.85 | Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience. ( Berti, I; Boccaletti, V; Carnevale, C; Cutrone, M; Dalmonte, P; Diociaiuti, A; El Hachem, M; Gesualdo, F; Greco, A; Neri, I; Oranges, T; Porcedda, G; Vercellino, N, 2017) |
| "Systemic propranolol is currently the first-line treatment modality for complicated infantile haemangiomas." | 3.85 | [Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment]. ( Ábrahám, R; Csoma, ZR; Dalmády, S; Kemény, L; Rácz, K; Rózsa, T, 2017) |
| "Propranolol hydrochloride has become the primary medical treatment for problematic infantile hemangioma; however, the expression of propranolol's target receptors during growth, involution, and treatment of hemangioma remains unclear." | 3.85 | Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas. ( Phillips, JD; Richter, GT; Wei, T; Zhang, H, 2017) |
| "Oral propranolol has been recently approved for infantile hemangiomas (IHs), but potential side effects stay a challenge." | 3.85 | Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. ( Parezanović, V; Petrovic, J; Topalovic, M; Trajkovic, G; Trifunovic, B; Vukomanovic, G, 2017) |
| "Concern has been raised about the potential long-term effects of propranolol treatment for infantile hemangioma (IH)." | 3.85 | Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age. ( Moyakine, AV; Spillekom-van Koulil, S; van der Vleuten, CJM, 2017) |
| "The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants." | 3.83 | Efficacy of propranolol for cutaneous hemangiomas in premature children. ( Barruscotti, S; Borroni, G; Brazzelli, V; Codazzi, CA; Giorgini, C; Mannarino, S; Marseglia, GL; Stronati, M; Tzialla, C, 2016) |
| "A retrospective observational study was conducted on patients with ulcerated infantile haemangioma treated with pulsed dye laser in association with propranolol." | 3.83 | [Combination of pulsed dye laser and propranolol in the treatment of ulcerated infantile haemangioma]. ( del Pozo Losada, J; Rodríguez-Ruiz, M; Tellado, MG, 2016) |
| "Oral propranolol is widely prescribed as first-line treatment for infantile haemangiomas (IHs)." | 3.83 | Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. ( Audrain, H; Baryschpolec, S; Baselga, E; Beattie, PE; Bhate, K; Bjerre, JV; Brown, SJ; Burrows, NP; Clayton, TH; Darne, S; Durack, A; Dvorakova, V; Flohr, C; Foelster-Holst, R; Gach, J; Glover, M; Goldstraw, N; Goodyear, H; Grabczynska, S; Greenblatt, D; Halpern, J; Hearn, RM; Hedelund, L; Hernandez-Martin, A; Hoeger, PH; Hoey, S; Hughes, B; Irvine, AD; Janmohamed, SR; Jayaraj, R; Johansson, EK; Laguda, B; Lam, M; Leech, S; McPherson, T; Morrison, D; Neri, I; O'Regan, GM; Oranje, AP; Patrizi, A; Porter, W; Ramesh, R; Ravenscroft, JC; Schill, T; Shahidullah, H; Shaw, L; Solman, L; Svensson, A; Taylor, AE; Taylor, R; Thomson, J; Tiffin, P; Tsakok, M; Wahlgren, CF; Wedgeworth, E, 2016) |
| "The aim of this study was to explore the efficacy and safety of propranolol in treating infantile haemangiomas, the most common benign vascular tumours in children." | 3.83 | Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. ( Jetsrisuparb, C; Komwilaisak, P; Panombualert, S; Techasatian, L; Uppala, R, 2016) |
| "From October 2010 to June 2014, 31 infantile hemangioma patients admitted to our hospital, were administered propranolol combined with betamethasone injection treatment of lesions." | 3.83 | Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone. ( Li, J; Shao, RZ; Zhao, DH, 2016) |
| " The medical records of infants with periorbital hemangiomas who were treated with systemic propranolol at a dose of 1." | 3.83 | Clinical Outcomes of Infants With Periorbital Hemangiomas Treated With Oral Propranolol. ( Liu, ZM; Sun, C; Wang, XK; Xu, DP; Xue, L, 2016) |
| "Propranolol, 2 mg/kg/day, is effective in the treatment of infantile hemangioma." | 3.83 | Response to propranolol in infantile hemangioma. ( Chunharas, A; Kadegasem, P; Lekanan, W; Sirachainan, N; Thammagasorn, Y; Wanitkun, S, 2016) |
| "An open observational prospective study was performed over 25 months in a group of pediatric patients diagnosed with infantile hemangioma treated with propranolol." | 3.83 | The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol. ( Castaneda, S; De la Cruz, H; Garcia, E; Melendez-Lopez, S; Sanchez-Palacio, J, 2016) |
| "There has been a dramatic increase in the off-label use of ophthalmic timolol maleate, a β-blocker used for infantile hemangioma (IH) treatment as a topical counterpart to oral propranolol." | 3.83 | Topical Timolol Maleate Treatment of Infantile Hemangiomas. ( Adams, D; Baselga, E; Drolet, B; Feigenbaum, D; Frieden, I; Garzon, MC; Holland, K; Horii, K; Lauren, C; Lucky, A; Mathes, E; McCuaig, C; Morel, KD; Newell, B; Nopper, A; Pope, E; Powell, J; Püttgen, K; Savva, Y; Siegel, D; Song, W, 2016) |
| "In recent years propranolol has become the treatment of choice for infantile hemangiomas (IHs)." | 3.83 | Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas? ( Krol, AL; Leitenberger, SL; MacArthur, CJ; Mann, JA; Tollefson, MM; Yarbrough, KB, 2016) |
| "Non-selective β-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response." | 3.83 | [Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Jiang, CH; Lei, SR; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016) |
| "Although propranolol has been accepted as a first-line drug for infantile haemangioma (IH), no study has systematically characterized changes in heart rates during long-term propranolol treatment." | 3.81 | Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment. ( Chen, W; Shi, H; Song, H; Wang, J; Yu, Y; Zhang, X; Zhou, H, 2015) |
| "The successful use of nadolol as an alternative to propranolol therapy in three cases of infantile hemangioma is reported." | 3.81 | Nadolol for the treatment of infantile hemangioma. ( Bautista-Paloma, FJ; Cotrina-Luque, J; Del Vayo-Benito, CA; Flores-Moreno, S; Villalba-Moreno, AM, 2015) |
| "Although consensus guidelines for pretreatment evaluation and monitoring of propranolol therapy in patients with infantile hemangiomas (IH) have been formulated, little is known about the cardiovascular side effects." | 3.81 | Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study. ( Breugem, CC; Breur, JM; de Graaf, M; Pasmans, SG; Raphael, MF; Slieker, MG; Vlasveld, FA, 2015) |
| "Intralesional compound betamethasone preparation is a feasible choice for the small-size hemangioma." | 3.81 | Intralesional injection of diprospan is effective for infantile hemangioma. ( Cui, L; Guo, Y; Hong, ZJ; Jiang, HQ; Yuan, SM; Zhang, M, 2015) |
| "Propranolol has been recently approved by health authorities to treat infantile haemangiomas (IH)." | 3.81 | [Propranolol in infantile hemangiomas]. ( Léauté-Labrèze, C, 2015) |
| "Topical propranolol has been used for the therapy of superficial infantile hemangiomas (IH)." | 3.81 | A novel topical nano-propranolol for treatment of infantile hemangiomas. ( Chen, ZG; Yuan, ML; Yuan, WE; Zhang, L; Zheng, JW, 2015) |
| "This study suggests that propranolol become the first-line treatment of choice for all haemangiomas." | 3.81 | Shouldn't Propranolol Be Used to Treat All Haemangiomas? ( Adams, KG; Adams, S; Hudson, DA; Moodley, ST, 2015) |
| "Our aim was to compare in a prospective study the clinical effects and safety of propranolol given orally, timolol maleate applied locally, and the combination of the two, in the management of superficial infantile haemangiomas." | 3.81 | Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. ( Cheng, C; Gong, H; Li, G; Li, YX; Wang, XK; Xu, DP, 2015) |
| "To explore the effect and safety of topical propranolol hydrochloride gel for treatment of infantile hemangioma." | 3.81 | [Effects of topical propranolol hydrochloride gel for treatment of infantile hemangioma in nude mice]. ( Chen, L; Chengjin, L; Lie, W; Qingjin, H; Shaoquan, C; Shuming, C; Yin, X; Zaizhong, Z, 2015) |
| "Propranolol is emerging as the treatment of choice for high-risk infantile haemangiomas." | 3.80 | Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure. ( McSwiney, E; Murphy, M; Murray, D, 2014) |
| "This study proved high efficiency of propranolol in treatment of infantile hemangioma, as assessed with the objective measures for the first time." | 3.80 | Treatment of infantile hemangiomas with propranolol: clinical guidelines. ( Anderson, W; Stewart, K; Szychta, P, 2014) |
| "Propranolol is highly effective in the treatment of infantile hemangioma (IH), but important clinical and pharmacological data are lacking." | 3.80 | Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. ( Ben Amitai, D; Lapidoth, M; Sagi, L; Zvulunov, A, 2014) |
| "A small percentage of complicated infantile haemangiomas need early, safe and effective treatment, and the option of off-label systemic propranolol treatment has been in existence since 2008." | 3.80 | A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. ( Cremer, HJ; Ruef, P; Schneider, M, 2014) |
| " Sixteen patients had recrudescence of IH off-treatment, with propranolol discontinued at a median age of 14 months (interquartile range 10-15 months)." | 3.80 | Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study). ( Castelo-Soccio, L; Chu, DH; Gelfand, JM; Perman, MJ; Shaddy, RE; Shah, KN; Treat, JR; Wan, J; Yan, AC, 2014) |
| "To assess the safety and efficacy of systemic propranolol for the treatment of complicated infantile haemangiomas." | 3.80 | Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. ( Glover, M; Gnarra, M; Harper, JI; Murabit, A; Solman, L; Syed, SB, 2014) |
| "This study was aimed at assessing the efficacy of propranolol treatment in infantile hemangiomas (IHs) by ultrasound." | 3.80 | Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. ( Shang, Y; Shi, H; Song, H; Wang, J; Xia, L; Yang, J; Zhou, H, 2014) |
| "Infantile hemangioma (IH) clearance may be slow or incomplete in response to pulsed dye laser (PDL) or propranolol alone." | 3.79 | Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser. ( Anolik, R; Bernstein, L; Blei, F; Brauer, JA; Brightman, L; Geronemus, RG; Hale, E; Karen, J; Reddy, KK; Waner, M; Weiss, E, 2013) |
| "Propranolol has been used successfully in a limited number of children with infantile hemangiomas (IHs)." | 3.79 | Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region. ( Kasimova, KR; Metellmann, HR; Podmelle, F; Sadykov, RA; Sadykov, RR, 2013) |
| "Propranolol is now widely used to treat severe infantile haemangiomas (IHs)." | 3.79 | Propranolol-resistant infantile haemangiomas. ( Aubert, H; Barbarot, S; Boccara, O; Bursztejn, AC; Caussé, S; Chiaverini, C; Dreyfus, I; Eschard, C; Hadj-Rabia, S; Mahé, E; Maruani, A; Mazereeuw-Hautier, J; Miquel, J; Puzenat, E; Saint-Jean, M; Stalder, JF, 2013) |
| "Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment." | 3.79 | Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. ( Ahogo, CK; Boralevi, F; Colona, V; Diallo, A; Ezzedine, K; Léauté-Labrèze, C; Prey, S; Taïeb, A, 2013) |
| "To evaluate the efficacy and safety of 1% propranolol ointment in the treatment of superficial infantile hemangiomas (IHs)." | 3.79 | [Treatment of superficial infantile hemangiomas with topical propranolol]. ( Huo, R; Lü, RR; Niu, JN; Xu, GQ, 2013) |
| "We sought to determine the effect of propranolol on cardiovascular and blood glucose parameters in infants with symptomatic infantile hemangiomas who were hospitalized for initiation of treatment, and to analyze adverse effects of propranolol throughout the course of inpatient and outpatient treatment." | 3.79 | Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. ( Bauman, NM; Boss, EF; Cohen, BA; Puttgen, KB; Schneider, J; Summerer, B, 2013) |
| "Propranolol was recently discovered to be an effective treatment for infantile haemangiomas, and varying doses and monitoring regimens have been proposed." | 3.78 | Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis. ( Dyme, JL; Han, EJ; Kotb, ME; Nyirenda, TL; Shin, HT; Thampan, A, 2012) |
| " The beta-blocker propranolol, known for its effectiveness on cutaneous hemangiomas, is also proving useful for the treatment of subglottic or visceral hemangiomas." | 3.78 | [Pediatrics]. ( Chevallay, M; de Buys Roessingh, A; El Ezzi, O; Fischer, CJ; Gehri, M; Giannoni, E; Hauschild, M; Hohlfeld, J; Pauchard, JY; Seneggen, E; Tolsa, JF; Truttmann, AC, 2012) |
| "A 33-day-old female with an ulcerated infantile hemangioma (IH) undergoing oral therapy with propranolol 2 mg/kg per day developed hyperkalemia and hyperphosphatemia 24 h after starting medication." | 3.78 | Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding? ( Buffon, RB; Cavalli, R; Colli, AM; de Souza, M; Gelmetti, C, 2012) |
| "Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)." | 3.78 | Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012) |
| "To evaluate changes in infantile hemangioma tissue before and after propranolol therapy, using gray-scale and color Doppler ultrasound imaging." | 3.78 | Propranolol reduces infantile hemangioma volume and vessel density. ( Bingham, MM; Perkins, JA; Saltzman, B; Vo, NJ, 2012) |
| " To evaluate the effectiveness, safety and tolerability of propranolol as single-agent treatment in patients with problematic, proliferative-phase, infantile hemangiomas (IHs)." | 3.78 | Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience. ( Georgountzou, A; Kakourou, T; Karavitakis, E; Klimentopoulou, A; Xaidara, A, 2012) |
| "Propranolol has recently emerged as an effective drug treatment for infantile haemangiomas." | 3.78 | Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. ( Bekhor, PS; Crock, CM; Penington, AJ; Phillips, RJ, 2012) |
| "Discuss effect and dynamics of propranolol (PR) treatment in infantile haemangioma (IH) of head and neck in children during follow-up." | 3.78 | Propranolol for infantile haemangioma: striking effect in the first weeks. ( Csákányi, Z; Gács, E; Gerlinger, I; Katona, G; Ráth, G; Szalai, Z, 2012) |
| "We report here the case of an infant with multiple hepatic and cutaneous infantile hemangiomas (IHs) associated with deranged liver function who was treated successfully with low-dose propranolol." | 3.77 | Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011) |
| "Recent reports have described the successful use of propranolol to treat severe hemangiomas of infancy." | 3.77 | [Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients]. ( Bernabeu-Wittel, J; Conejo-Mir, J; de Agustín, JC; Fernández-Pineda, I; Mantrana-Bermejo, ME; Pereyra-Rodríguez, JJ, 2011) |
| "Four children with haemangiomas of the head and neck were treated with propranolol at a tertiary referral centre." | 3.77 | Failure of propranolol in the treatment of childhood haemangiomas of the head and neck. ( Bruce, IA; Goswamy, J; Rothera, MP, 2011) |
| "We report the rapid and dramatic efficacy of propranolol in 8 infants with infantile hepatic hemangiomas." | 3.76 | Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. ( Ammour, A; Benlahrech, S; Bodemer, C; Broue, P; Hoeger, PH; Labenne, M; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Ohanessian, G; Rössler, J; Vabres, P; Vial, J, 2010) |
| " She was given propranolol after her tracheotomy and had a significant reduction in her subglottic airway obstruction." | 3.76 | Propranolol in the management of airway infantile hemangiomas. ( Frieden, IJ; Maguiness, SM; Meyer, AK; Rosbe, KW; Suh, KY, 2010) |
| "Propranolol treatment was recently reported to be successful for the management of severe infantile hemangioma." | 3.76 | Hyperkalemia complicating propranolol treatment of an infantile hemangioma. ( Kietz, S; Lakomek, M; Lauerer, P; Pavlakovic, H; Zutt, M, 2010) |
| "There are recent reports of effective treatment of cutaneous hemangiomas with Propranolol." | 3.75 | Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. ( Denoyelle, F; Enjolras, O; Garabedian, EN; Harris, R; Leboulanger, N; Roger, G, 2009) |
| "All animals of group 2 (which received propranolol orally and in addition intradermal injections of adjuvant) developed psoriasiform epidermal hyperplasia with acanthosis." | 3.69 | Induction of psoriasiform changes in guinea pig skin by propranolol. ( Brenner, S; Shechter, H; Wolf, R, 1994) |
| " We observed no serious adverse events." | 3.11 | Efficacy and Safety of Propranolol Gel for Infantile Hemangioma: A Randomized, Double-Blind Study. ( Hanawa, M; Ishii, I; Kawasaki, Y; Mitsukawa, N; Rikihisa, N; Shiko, Y; Suzuki, T; Takatsuka, H, 2022) |
| " As an outpatient therapy, propranolol was found to be safe for Chinese children and to have minor side effects." | 2.82 | Is Propranolol Safe and Effective for Outpatient Use for Infantile Hemangioma? A Prospective Study of 679 Cases From One Center in China. ( Chang, L; Chen, H; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Wang, T; Yang, X; Ye, X; Yu, W, 2016) |
| " Our study suggested that oral propranolol combined with topical timolol treatment is very effective and well-tolerated for compound IHs, which can be used as a first line treatment." | 2.82 | Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. ( Ge, J; Yuan, W; Zhang, L; Zhao, H; Zheng, J, 2016) |
| "Atenolol is a cardioselective beta-blocker that may have fewer adverse events." | 2.79 | Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study. ( Ábarzúa-Araya, A; Heusser, F; Navarrete-Dechent, CP; Retamal, J; Zegpi-Trueba, MS, 2014) |
| "Propranolol treatment decreases urinary excretion of MMP-9 in patients with IH." | 2.78 | Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. ( Bauman, N; Brown, KJ; Movius, E; Preciado, D; Saieg, A; Thaivalappil, S, 2013) |
| "Infantile haemangioma is the commonest childhood tumour and approximately 10% requires treatment." | 2.76 | Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. ( Gorst, C; Holmes, WJ; Liew, SH; Mishra, A, 2011) |
| " Propranolol can commence for most infants in the outpatient setting and the most frequently employed dosing regimen is 1 mg/kg twice daily." | 2.72 | Infantile hemangioma. Part 2: Management. ( Rodríguez Bandera, AL; Sebaratnam, DF; Wargon, O; Wong, LF, 2021) |
| " We review the indications, dosing regimens, duration of treatment, efficacy and adverse effects of propranolol, and therapeutic alternatives including oral atenolol, acebutolol, nadolol, intralesional propranolol injections, topical propranolol and timolol, and oral captopril." | 2.66 | β-blocker therapy for infantile hemangioma. ( Koh, SP; Leadbitter, P; Smithers, F; Tan, ST, 2020) |
| "To evaluate the medical literature on the use of β-blockers, through different routes, for the treatment of periorbital infantile hemangiomas and to summarize the recommendations available on dosage and monitoring." | 2.61 | β-blockers in the treatment of periocular infantile hemangioma. ( Al-Haddad, C; El Moussawi, Z; El Salloukh, NA, 2019) |
| "Cutaneous hemangiomas are the most frequent benign tumors in children." | 2.61 | Role of Magnetic Resonance Image in Children with Lumbosacral and Perineal Hemangiomas: Case Reports and Review of the Literature. ( Barreda-Solana, M; Correa-González, N; García-Rabasco, A; Ortiz-Salvador, JM; Subiabre-Ferrer, D, 2019) |
| "Infantile haemangiomas are the most common tumour of infancy." | 2.58 | Topical propranolol for infantile haemangiomas: a systematic review. ( Birchall, JC; Elhassan, HA; Mcleod, RWJ; Price, A; Rai, S, 2018) |
| "While options for treatment strategies for infantile hemangiomas (IH) are numerous, evidence-based information about agents, optimal dosage, adverse effects, treatment modality, pretreatment and treatment strategies remain limited." | 2.53 | Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature. ( Breugem, CC; Breur, JM; Elbert, NJ; Kon, M; Liem, YT; Pasmans, SG; Raphael, MF; Vlasveld, FA, 2016) |
| "Propranolol has revolutionized the treatment of infantile hemangiomas, and other beta-blockers provide promising alternatives." | 2.52 | Beta-blockers for childhood vascular tumors. ( Bayart, CB; Brandling-Bennett, HA, 2015) |
| "Our observations show that gradually increasing the dosage of propranolol up to 3 mg/kg and gradually weaning the dosage is safe and effective in treatment of problematic IH." | 2.50 | Treatment of problematic infantile hemangiomas with propranolol: a series of 40 cases and review of the literature. ( Dębek, W; Dzienis-Koronkiewicz, E; Hermanowicz, A; Matuszczak, E; Oksiuta, M; Tylicka, M, 2014) |
| "Infantile hemangioma is the most common vascular tumor of childhood." | 2.49 | [What's new about infantile hemangiomas?]. ( Dreyfus, I; Maza, A; Mazereeuw-Hautier, J, 2013) |
| "Haemangioma is a vascular tumour of infancy that is well known for its rapid growth during the first weeks to months of a child's life, followed by a spontaneous but slow involution." | 2.49 | Pathogenesis of infantile haemangioma. ( Bischoff, J; Greenberger, S, 2013) |
| "Propranolol treatment (2." | 2.49 | Propranolol treatment in life-threatening airway hemangiomas: a case series and review of literature. ( Broeks, IJ; Dassel, AC; Hermans, DJ; van Beynum, IM; van der Vleuten, CJ, 2013) |
| "Hemangiomas are benign neoplasms of the vasculature frequently encountered in children." | 2.47 | Hemangiomas - current therapeutic strategies. ( Mabeta, P; Pepper, MS, 2011) |
| "Infantile hemangiomas are benign vascular tumors that affect 8-12 % of infants." | 2.46 | [Propanolol used in treatment of infantile hemangioma]. ( Guldbakke, KK; Hanssen, HK; Huldt-Nystrøm, T; Høivik, F; Rørdam, OM, 2010) |
| "Propranolol was started in 30." | 1.91 | Management of infantile hemangiomas-experience of a tertiary hospital. ( Álvares, S; Banquart Leitão, J; Barbosa-Sequeira, J; Correia, MR; Fernandes, A; Fraga, C; Gomes, R; Paiva Coelho, M; Salazar, L, 2023) |
| "Propranolol treatment mostly leads to regression of hemangiomas with satisfactory aesthetic results, but unfortunately not in all cases." | 1.91 | Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment. ( Avitan-Hersh, E; Khamaysi, Z; Pam, N; Zaaroura, H, 2023) |
| " A propranolol dosage level of less than 3 mg/kg/day protected against early relapse [OR = 0." | 1.91 | Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: A case-control study using the 2014-2021 French Ouest DataHub. ( Abasq, C; Adamski, H; Barbarot, S; Beuchée, A; Bouzillé, G; Chrétien, JM; Descatha, A; Droitcourt, C; Dupuy, A; Goronflot, T; Gourraud, PA; Happe, A; Herbert, J; Martin, L; Maruani, A; Mauguen, C; Oger, E, 2023) |
| " To evaluate the correlation of clinical features between cutaneous IH and IHH, as well as efficacy of systemic propranolol in the treatment of cutaneous IH combined with IHH." | 1.91 | Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment. ( Han, X; Li, L; Ma, L; Sun, Y; Wei, L; Xu, Z; Yu, L; Zhang, B, 2023) |
| "Oral propranolol has not been shown to impact physical development, such as weight and height." | 1.91 | The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment. ( Chen, S; Chen, X; Deng, L; Gao, J; Huang, L; Lin, X; Liu, C; Wang, Q; Wang, T, 2023) |
| "Propranolol was successfully tapered over 3 weeks by reducing the dose by 50% weekly until it reached the therapeutic dose." | 1.91 | Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report. ( Alessa, A; Alghanem, A; Alhammad, AM; Alshammari, H; Elsharawy, Y, 2023) |
| " Adverse event and drug-related adverse event rates were 87." | 1.72 | Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study. ( Hakamata, A; Hayano, S; Inui, N; Iwashima, S; Kashiwagura, Y; Nagata, E; Nishida, M; Odagiri, K; Okada, E; Sano, S; Tanaka, S; Uchida, S; Umemura, K; Watanabe, H, 2022) |
| "Infantile hemangiomas are the most common benign vascular tumours in infants." | 1.72 | Evaluation of cases with infantile hemangioma requiring treatment. ( Acipayam, C; Dalgiç, EF; Dinçer, S; Güllü, UU; Karaküçük, SN; Maraşli, H; Yurttutan, S, 2022) |
| "Propranolol is a safe, effective and well-tolerated treatment in Australian children with IH." | 1.72 | Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019. ( Adams, L; Ryan, E, 2022) |
| "Severe hypoglycemia was common in infants aged >1 year, when PPL was used for ≥6 months." | 1.72 | Severe hypoglycemia in propranolol treatment for infantile hemangiomas. ( Baba, N; Kaneko, T; Kuwano, Y; Morimoto, A; Ozeki, M; Sasaki, S, 2022) |
| "Oral propranolol was effective in the treatment of pIH." | 1.72 | Comprehensive Management of Infantile Hemangiomas Involving the Periorbital Region. ( Chen, WL; Dong, XY; Hong, L; Lan, YQ, 2022) |
| " The propranolol starting dosage was 0." | 1.72 | Monitoring oral propranolol for infantile hemangiomata. ( Bar, J; Bar-Ilan, E; Cleper, R; Mashiah, J; Samuelov, L; Sprecher, E, 2022) |
| "Oral propranolol has been well established as the first-line treatment of complicated hemangiomas; however, variability in the administration protocol remains." | 1.62 | Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol. ( Johansen, ML; Lawley, LP; Mahendran, G, 2021) |
| "Persistent cutaneous dysesthesias were present in seven patients, in most cases many years after completion of involution." | 1.62 | Persistent dysesthesias in involuted infantile hemangiomas: An uncommon complication in a common condition. ( Antaya, RJ; Braun, M; Frieden, IJ; Kohn, LL; Mancini, AJ; Metry, D, 2021) |
| "Mean propranolol treatment duration was 11." | 1.62 | Infantile Hemangiomas Cleared by Combined Therapy With Pulsed Dye Laser and Propranolol. ( Aoki, R; Ogawa, R; Sugimoto, A; Toyohara, E, 2021) |
| "Propranolol was interrupted after complete or almost complete resolution of infantile haemangiomas." | 1.56 | Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review. ( Carnevale, C; Diociaiuti, A; El Hachem, M; Figà-Talamanca, L; Léauté-Labrèze, C; Neri, I; Rotunno, R; Torres, EB, 2020) |
| " Although oral propranolol is currently first-line therapy, optimal dosing for treatment of IH remains debated." | 1.56 | Retrospective case series of increased oral propranolol dosage for infantile hemangiomas. ( Aggarwal, P; Cohen, BA; Huang, AH; Mahon, M; Mannschreck, D, 2020) |
| "The propranolol treatment group exhibited a remarkable difference as compared with the other group." | 1.56 | The impact of propranolol on apoptosis in cutaneous squamous cell carcinomas. ( Celik, E; Kaplan, HM; Singirik, E, 2020) |
| "Infantile hemangiomas are the most common vascular tumors in childhood." | 1.56 | Evaluation of Clinical Properties and Treatment Responses of Infantile Hemangioma. ( Azizoglu, M; Corapcioglu, F; Demirsoy, U; Yildirimcakar, D, 2020) |
| "Propranolol was tested on four UM and two CM cell lines to determine the effects of this beta-blocker." | 1.51 | Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma. ( Burnier, JV; Burnier, MN; Bustamante, P; de Alba Graue, PG; Dias, AB; Goyeneche, A; Jin, E; Miyamoto, D; Tsering, T, 2019) |
| "Propranolol is the treatment of choice for complicated IH." | 1.51 | [Infantile haemangioma: an update]. ( Ott, H; Reimer, A, 2019) |
| "Propranolol treatment (2 mg/kg/day in three doses) for infantile haemangioma is well tolerated and safe and may be administered and monitored in an ambulatory setting." | 1.48 | Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day-care hospitalization setting. ( Atar Snir, V; Ben-Amitai, D; Fogel, I; Friedland, R; Lapidoth, M; Ollech, A; Valdman-Greenshpon, Y; Zvulunov, A, 2018) |
| "Infantile hemangiomas are the most common tumor of childhood and undergo rapid growth during early infancy followed by gradual involution." | 1.48 | Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. ( Kagami, S; Kaneko, M; Katori, T; Kishi, A, 2018) |
| "The propranolol treatment for the patient with suspected of bronchial asthma was suspended for 4 months." | 1.48 | Oral propranolol for infantile hemangiomas beyond the proliferative phase. ( Kagami, S; Katori, T, 2018) |
| "Subglottic hemangiomas are a rare presentation of infantile hemangiomas but with significant morbidity." | 1.48 | Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution. ( Azbell, C; Grunwaldt, L; Jabbour, N; McCormick, AA; Tarchichi, T, 2018) |
| "Tufted angioma is a benign vascular proliferation which presents most commonly in infants and children and could occasionally be complicated by Kasabach-Merritt syndrome." | 1.48 | Tufted angioma arising at the site of hepatitis B vaccination: A case report. ( Hajizadeh, J; Jowkar, F; Sari-Aslani, F; Sepaskhah, M, 2018) |
| " The dosage of propranolol was increased from 0." | 1.46 | Successful Treatment of Infantile Hemangiomas With Propranolol in Low-Birth-Weight Infants. ( Hayashi, A; Kado, M; Matsumura, T; Mizuno, H; Mochizuki, M; Shimizu, A, 2017) |
| "Oral propranolol has become first-line intervention for problematic infantile hemangioma (IH) that is not amenable to topical or intralesional therapies." | 1.46 | Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma. ( Alomari, MH; Goss, JA; Greene, AK; Konczyk, DJ; Maclellan, RA, 2017) |
| "Propranolol is an effective drug in treating IH." | 1.46 | Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol. ( Alvarenga, JG; Bouer, M; de Oliveira Labinas, GH; de Oliveira, ZN; Rivitti-Machado, MC; Rotter, A; Samorano, LP; Santos, PC; Silvestre, DA, 2017) |
| "Propranolol 4% gel is a safe and efficient topical therapy for IH." | 1.46 | Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas. ( Goldberg, I; Harel, A; Ilan, EB; Kutz, A; Mashiah, J; Rabia, SH; Sprecher, E, 2017) |
| " The adverse events (AEs) were observed." | 1.46 | Efficacy and Safety of 2% Topical Propranolol Cream for the Treatment of Proliferating Infantile Strawberry Hemangiomas. ( Lu, Y; Wang, Y; Yang, Y; Zhang, J; Zhang, X, 2017) |
| "Propranolol is a safe and effective first-line therapy for problematic IHs." | 1.43 | Propranolol Therapy for Problematic Infantile Hemangioma. ( Knuth, C; Murthy, A; Ng, M; Weisbrod, C, 2016) |
| "Hemangiomas are common skin lesion, affecting 10-12% of children <1year of age." | 1.43 | The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser. ( Dementieva, N; Jones, S, 2016) |
| "Oral propranolol was successful in 95." | 1.43 | Propranolol treatment for infantile hemangioma: a case series of sixty-two patients. ( Barbato, G; Boccaletti, V; Carano, N; Cerasoli, G; Gritti, A; Lombardi, AA; Marchesi, M; Stringari, G; Tchana, B; Zanzucchi, M, 2016) |
| " However, the appropriate drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects remains controversial." | 1.43 | [Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Li, K; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016) |
| "Propranolol treatment delayed primary tumor growth and metastases development in MT/Ret mice." | 1.43 | Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma. ( Bod, L; Jean Wrobel, L; Kato, M; Le Gal, FA; Lengagne, R; Prévost-Blondel, A, 2016) |
| "Propranolol was commenced at 0." | 1.42 | Low-dose propranolol regimen for infantile haemangioma. ( Itinteang, T; Leadbitter, P; Marsh, R; Tan, CE; Tan, ST, 2015) |
| "Infantile hemangiomas are the most common vascular tumors in childhood." | 1.42 | Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report. ( del Boz González, J; Navarro Morón, J; Porcel Chacón, R, 2015) |
| "Propranolol was initiated at 0." | 1.42 | Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS). ( de Laat, PC; Janmohamed, SR; Madern, GC; Oranje, AP; van Oosterhout, M; van Rosmalen, J, 2015) |
| "Propranolol gel may suppress the proliferation of IHs by reducing VEGF." | 1.42 | Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas. ( Chen, JW; Chen, SM; Chen, SQ; Li, CJ; Tang, YJ; Wang, L; Xia, Y; Yuan, B; Zhang, ZZ, 2015) |
| "Propranolol has been the first-line treatment for problematic infantile hemangioma (IH) since 2008." | 1.40 | Recurrence of infantile hemangioma after termination of propranolol treatment. ( Chang, L; Chen, H; Hu, X; Jin, Y; Lin, X; Ma, G; Qiu, Y; Yang, X; Ye, X; Yu, W, 2014) |
| "Propranolol (a β-blocker) is a safe treatment for problematic IH." | 1.40 | Propranolol in infantile haemangioma: simplifying pretreatment monitoring. ( de Buys Roessingh, A; El Ezzi, O; Hohlfeld, J, 2014) |
| "Propranolol, has been quickly adopted as the first line medical treatment for complicated infantile hemangioma; and it is the only treatment to have a marketing authorization in this indication." | 1.40 | [Infantile hemangiomas: the revolution of beta-blockers]. ( Leaute-Labreze, C, 2014) |
| "To evaluate the efficacy, adverse effects, and recurrence of oral propranolol for treatment of infantile hemangioma." | 1.39 | Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence. ( Li, Q; Xiao, Q; Yu, W; Zhang, B, 2013) |
| " The most important adverse effects were hypotension (3·4%), wheezing (9·2%), nocturnal restlessness (22·4%) and cold extremities (36·2%)." | 1.39 | Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. ( Bauland, CG; Hermans, DJ; van Beynum, IM; van der Vleuten, CJ; Zweegers, J, 2013) |
| "Propranolol has recently been introduced as a novel pharmacologic treatment for infantile haemangiomas, after Leaute-Labreze and colleagues observed that two patients being treated for cardiac indications had rapid regression of their haemangiomas." | 1.39 | Capillary haemangioma successfully treated with oral beta-blocker in Dar es Salaam, Tanzania: a case report. ( Blaikie, A; Cloke, A; Lim, LT, 2013) |
| "Oral propranolol was clinically effective in reducing the volume and color of infantile hemangiomas, although the reduction was not complete and telangiectasia and scarring persisted after treatment." | 1.38 | Outpatient treatment of infantile hemangiomas with propranolol: a prospective study. ( Betlloch-Mas, I; Lucas-Costa, A; Martin de Lara, AI; Martínez-Miravete, MT; Selva-Otalaurruchi, J, 2012) |
| "Oral propranolol was started in an ambulatory way at a dose of 2mg/kg daily divided in two doses." | 1.38 | Oral propranolol for treating infantile hemangiomas: a case series of 57 patients. ( Abarzúa-Araya, A; Navarrete-Dechent, C; Nicklas-Díaz, C; Silva-Valenzuela, S; Uribe-González, P; Zegpi-Trueba, MS, 2012) |
| "Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3." | 1.37 | Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. ( Hermans, DJ; Schultze Kool, LJ; van Beynum, IM; van de Kerkhof, PC; van der Vleuten, CJ; Wijnen, MH, 2011) |
| "Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH." | 1.37 | Propranolol for treatment of ulcerated infantile hemangiomas. ( Barbarot, S; Bodak, N; Hadj-Rabia, S; Hamel-Teillac, D; Kupfer-Bessaguet, I; Lacour, JP; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Naouri, M; Nguyen, JM; Saint-Jean, M; Stalder, JF; Vabres, P, 2011) |
| "Kaposiform hemangioendothelioma is a rare vascular tumor in children." | 1.37 | Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment. ( de Blaauw, I; Hermans, DJ; Kool, LJ; van Beynum, IM; van der Vijver, RJ; van der Vleuten, CJ, 2011) |
| "Propranolol appears to be an effective treatment option for IH even in the nonproliferative phase and after the first year of life." | 1.37 | Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. ( Breugem, CC; Breur, JMPJ; de Graaf, M; Pasmans, SGMA; Raphaël, MF; Vos, M, 2011) |
| " A dosage of 2 mg/kg/d, is usually employed with a dosing interval of 8 hours." | 1.37 | [Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations]. ( López-Gutiérrez, JC; Ruiz-Rodriguez, R; Sánchez-Carpintero, I, 2011) |
| "PHACE syndrome is a neurocutaneous disorder with large facial segmental hemangionas associated with anomalies of the brain, eye, heart and aorta." | 1.37 | Use of propranolol for treatment of hemangiomas in PHACE syndrome. ( Deming, D; Hopper, A; Merritt, TA; Ninnis, J; Solomon, T, 2011) |
| "Oral propranolol was given for a period of 6 months with monthly follow up." | 1.37 | Initial experiences with propranolol treatment of infantile hemangiomas: report of three cases. ( Halilbasic, A; Halilbasic, M; Hotic, N; Husaric, E; Husaric, S; Rahmanovic, E, 2011) |
| "Propranolol was given to 32 children (21 girls; mean age at onset of treatment: 4." | 1.35 | Propranolol for severe infantile hemangiomas: follow-up report. ( Berge, J; Boralevi, F; de la Roque, ED; Dupuis, E; Ezzedine, K; Grenier, N; Léauté-Labrèze, C; Lipsker, D; Mazereeuw-Hautier, J; Sans, V; Taïeb, A; Vergnes, P, 2009) |
| "Hemangioma is the most common tumor of infancy." | 1.35 | [Response to oral propranolol therapy for ulcerated hemangiomas in infancy]. ( Michel, JL; Patural, H, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.59) | 18.7374 |
| 1990's | 1 (0.30) | 18.2507 |
| 2000's | 7 (2.07) | 29.6817 |
| 2010's | 246 (72.78) | 24.3611 |
| 2020's | 82 (24.26) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Q | 1 |
| Long, J | 1 |
| Hu, L | 2 |
| Chen, Z | 2 |
| Li, Q | 2 |
| Hu, G | 1 |
| Pandey, V | 1 |
| Tiwari, P | 1 |
| Imran, M | 1 |
| Mishra, A | 3 |
| Kumar, D | 1 |
| Sharma, SP | 1 |
| Cotter, C | 1 |
| Solman, L | 4 |
| Flohr, C | 3 |
| Colmant, C | 1 |
| Powell, J | 3 |
| Rikihisa, N | 1 |
| Takatsuka, H | 1 |
| Suzuki, T | 1 |
| Shiko, Y | 1 |
| Kawasaki, Y | 1 |
| Hanawa, M | 1 |
| Ishii, I | 1 |
| Mitsukawa, N | 1 |
| Schmid, F | 1 |
| Hoeger, PH | 6 |
| Nikfarjam, U | 1 |
| Wegner, J | 1 |
| Grabbe, S | 1 |
| Schepler, H | 1 |
| Juchems, E | 1 |
| Yu, L | 2 |
| Wei, L | 2 |
| Xu, Z | 3 |
| Zhang, B | 3 |
| Han, X | 2 |
| Sun, Y | 2 |
| Liu, Y | 1 |
| Wang, C | 2 |
| Qiu, L | 1 |
| Xiu, B | 1 |
| He, R | 1 |
| Li, L | 3 |
| Ma, L | 2 |
| Pahl, KS | 1 |
| McLean, TW | 3 |
| Baselga, E | 8 |
| El Hachem, M | 3 |
| Diociaiuti, A | 3 |
| Carnevale, C | 3 |
| Downey, C | 2 |
| Roe, E | 1 |
| Mascaro, P | 1 |
| Neri, I | 4 |
| Leuzzi, M | 1 |
| Bernabeu-Wittel, J | 2 |
| Monserrat-García, MT | 1 |
| Ortiz-Prieto, A | 1 |
| Torrelo, A | 2 |
| Knopfel, N | 3 |
| Vercellino, N | 3 |
| Manunza, F | 1 |
| Oranges, T | 3 |
| Bassi, A | 1 |
| Gonzalez-Enseñat, MA | 1 |
| Vicente, A | 1 |
| Gich, I | 1 |
| Puig, L | 1 |
| Meyer-Mueller, C | 1 |
| Nicholson, C | 1 |
| Polcari, I | 1 |
| Boull, C | 1 |
| Maguiness, S | 1 |
| Twist, J | 1 |
| Chen, A | 2 |
| Poffenberger, P | 1 |
| Zinn, Z | 2 |
| Gatts, JE | 1 |
| Rush, MC | 1 |
| Check, JF | 1 |
| Samelak, DM | 1 |
| Kashiwagura, Y | 2 |
| Hakamata, A | 2 |
| Shirai, M | 1 |
| Endoh, A | 1 |
| Tanaka, S | 2 |
| Inui, N | 2 |
| Watanabe, H | 2 |
| Namiki, N | 1 |
| Uchida, S | 2 |
| Chang, SJ | 4 |
| Chang, HF | 2 |
| Qiu, Y | 8 |
| Chang, L | 8 |
| Jin, Y | 6 |
| Lin, X | 9 |
| Nagata, E | 1 |
| Okada, E | 1 |
| Sano, S | 1 |
| Nishida, M | 1 |
| Hayano, S | 1 |
| Iwashima, S | 1 |
| Odagiri, K | 1 |
| Umemura, K | 1 |
| Salido-Vallejo, R | 1 |
| González-Menchen, A | 1 |
| Alcántara-Reifs, C | 1 |
| España, A | 1 |
| Hung, YT | 1 |
| Chung, WH | 1 |
| Chen, CB | 1 |
| Maraşli, H | 1 |
| Acipayam, C | 1 |
| Güllü, UU | 1 |
| Dinçer, S | 1 |
| Dalgiç, EF | 1 |
| Karaküçük, SN | 1 |
| Yurttutan, S | 1 |
| Pensabene, M | 1 |
| Di Pace, MR | 1 |
| Baldanza, F | 1 |
| Grasso, F | 1 |
| Patti, M | 1 |
| Sergio, M | 1 |
| La Placa, S | 1 |
| Giuffre', M | 1 |
| Serra, G | 1 |
| Casuccio, A | 1 |
| Cimador, M | 3 |
| Adams, L | 1 |
| Ryan, E | 1 |
| Dong, J | 1 |
| Rong, H | 1 |
| Dong, Z | 1 |
| Wang, T | 3 |
| Liu, S | 1 |
| Morimoto, A | 1 |
| Ozeki, M | 2 |
| Sasaki, S | 1 |
| Baba, N | 1 |
| Kuwano, Y | 2 |
| Kaneko, T | 1 |
| Chen, WL | 2 |
| Lan, YQ | 1 |
| Hong, L | 1 |
| Dong, XY | 1 |
| Bar, J | 1 |
| Bar-Ilan, E | 2 |
| Cleper, R | 1 |
| Sprecher, E | 2 |
| Samuelov, L | 1 |
| Mashiah, J | 4 |
| Tirelli, LL | 1 |
| Luna, PC | 1 |
| Panizzardi, AA | 1 |
| Larralde, M | 1 |
| Huang, H | 2 |
| Chen, X | 3 |
| Cai, B | 1 |
| Yu, J | 1 |
| Wang, B | 1 |
| Hasbani, DJ | 1 |
| Hamie, L | 1 |
| Yang, E | 1 |
| Wang, X | 1 |
| Huang, S | 2 |
| Li, M | 2 |
| Li, Y | 1 |
| Geng, Y | 1 |
| Liu, X | 2 |
| Zhang, D | 1 |
| Wu, H | 1 |
| Léauté-Labrèze, C | 12 |
| Frieden, I | 3 |
| Delarue, A | 2 |
| Benetton, C | 2 |
| Pace, MD | 2 |
| De Corti, F | 2 |
| Gamba, P | 2 |
| Midrio, P | 2 |
| Pandey, A | 1 |
| Srivastava, A | 1 |
| Pant, N | 1 |
| Singh, S | 1 |
| Rawat, J | 1 |
| Gomes, R | 1 |
| Salazar, L | 1 |
| Fraga, C | 1 |
| Correia, MR | 1 |
| Barbosa-Sequeira, J | 1 |
| Fernandes, A | 1 |
| Álvares, S | 1 |
| Banquart Leitão, J | 1 |
| Paiva Coelho, M | 1 |
| Nyers, E | 1 |
| Perry, DM | 1 |
| De Jesús, G | 1 |
| Chen, Q | 2 |
| Zhou, L | 1 |
| Gao, W | 2 |
| Yu, Z | 2 |
| Chen, J | 2 |
| Li, H | 1 |
| Yamada-Kanazawa, S | 1 |
| Shimada, S | 1 |
| Nakayama, W | 1 |
| Sawamura, S | 1 |
| Nishimura, Y | 1 |
| Kajihara, I | 1 |
| Makino, K | 1 |
| Aoi, J | 1 |
| Masuguchi, S | 1 |
| Amano, F | 1 |
| Fukushima, S | 1 |
| Beqo, BP | 1 |
| Gasparella, P | 1 |
| Flucher, C | 1 |
| Spendel, S | 1 |
| Quehenberger, F | 1 |
| Haxhija, EQ | 1 |
| Fu, R | 1 |
| Zou, Y | 1 |
| Wu, Z | 2 |
| Jin, P | 1 |
| Cheng, J | 1 |
| Bai, H | 1 |
| Huang, M | 1 |
| Huan, X | 1 |
| Yuan, H | 1 |
| Höger, PH | 2 |
| Hamm, H | 1 |
| Wu, Y | 1 |
| Zhao, P | 1 |
| Song, W | 2 |
| Lu, W | 1 |
| Dai, T | 1 |
| Wang, L | 7 |
| Gonzalez Martinez, OG | 1 |
| Langer, PD | 1 |
| Milman, T | 1 |
| Khamaysi, Z | 3 |
| Pam, N | 3 |
| Zaaroura, H | 1 |
| Avitan-Hersh, E | 1 |
| Mauguen, C | 1 |
| Maruani, A | 4 |
| Barbarot, S | 3 |
| Abasq, C | 1 |
| Martin, L | 2 |
| Herbert, J | 1 |
| Goronflot, T | 1 |
| Gourraud, PA | 1 |
| Happe, A | 1 |
| Descatha, A | 1 |
| Chrétien, JM | 1 |
| Beuchée, A | 1 |
| Adamski, H | 1 |
| Dupuy, A | 2 |
| Bouzillé, G | 1 |
| Oger, E | 1 |
| Droitcourt, C | 1 |
| Liu, C | 2 |
| Deng, L | 1 |
| Wang, Q | 2 |
| Huang, L | 1 |
| Gao, J | 1 |
| Chen, S | 5 |
| Hali, F | 1 |
| Moubine, I | 1 |
| Berrami, H | 1 |
| Serhier, Z | 1 |
| Othmani, MB | 1 |
| Chiheb, S | 1 |
| Borst, AJ | 1 |
| Hammill, AM | 1 |
| Iacobas, I | 1 |
| Atkinson, A | 1 |
| Shah, T | 1 |
| Margolin, JF | 1 |
| Bayliff, SL | 1 |
| Blatt, J | 1 |
| Shang, Y | 2 |
| Alshammari, H | 1 |
| Alessa, A | 1 |
| Elsharawy, Y | 1 |
| Alghanem, A | 1 |
| Alhammad, AM | 1 |
| Al-Haddad, C | 1 |
| El Salloukh, NA | 1 |
| El Moussawi, Z | 1 |
| Pino, G | 1 |
| Zambrano, MJ | 1 |
| Kramer, D | 1 |
| Cervilla, K | 1 |
| González, S | 1 |
| Qiao, C | 1 |
| Ma, G | 5 |
| de Wild, SR | 1 |
| Moyakine, AV | 4 |
| van der Vleuten, CJM | 3 |
| Bustamante, P | 1 |
| Miyamoto, D | 1 |
| Goyeneche, A | 1 |
| de Alba Graue, PG | 1 |
| Jin, E | 1 |
| Tsering, T | 1 |
| Dias, AB | 1 |
| Burnier, MN | 1 |
| Burnier, JV | 1 |
| Bessar, H | 1 |
| Kandil, AH | 1 |
| Nasr, NM | 1 |
| Khattab, F | 1 |
| Chelleri, C | 1 |
| Monzani, NA | 1 |
| Gelmetti, C | 3 |
| Milani, GP | 1 |
| Fossali, EF | 1 |
| Galeone, C | 1 |
| Cavalli, R | 3 |
| Tan, JMC | 1 |
| Lim, HW | 1 |
| Koh, MJ | 1 |
| Oesch, V | 1 |
| Theiler, M | 2 |
| Szello, P | 1 |
| Weibel, L | 3 |
| Aizman, L | 1 |
| Van Den Anker, J | 1 |
| Tender, J | 1 |
| Krishnan, A | 1 |
| Kirkorian, AY | 1 |
| Kridin, K | 2 |
| Bergman, R | 1 |
| Robert, J | 1 |
| Tavernier, E | 1 |
| Boccara, O | 2 |
| Mazereeuw-Hautier, J | 8 |
| Püttgen, KB | 5 |
| Hansen, LM | 1 |
| Lauren, C | 2 |
| Stefanko, N | 1 |
| Mathes, E | 2 |
| Olsen, GM | 1 |
| Tollefson, MM | 3 |
| Adams, D | 2 |
| Chamlin, S | 1 |
| Corey, K | 1 |
| Frascari, FF | 1 |
| Frieden, IJ | 8 |
| Galligan, ER | 1 |
| Gupta, D | 1 |
| Haggstrom, A | 1 |
| Horii, K | 2 |
| Hornik, CP | 1 |
| Klajn, J | 1 |
| Liberman, L | 1 |
| Mancini, A | 1 |
| Mannschreck, D | 2 |
| McGinness, A | 1 |
| McCuaig, C | 3 |
| Newell, B | 2 |
| Nguyen, H | 1 |
| Nopper, A | 2 |
| Oyesanya, T | 1 |
| Reynolds, M | 1 |
| Rios, M | 1 |
| Siegel, DH | 1 |
| Ward, K | 1 |
| Garzon, MC | 4 |
| Frommelt, P | 1 |
| Drolet, BA | 4 |
| Sun, LM | 1 |
| Xu, Y | 1 |
| Xu, MN | 1 |
| Wang, M | 1 |
| Su, Y | 1 |
| Yuan, SM | 2 |
| Koren, A | 1 |
| Friedman, O | 1 |
| Zur, E | 1 |
| Artzi, O | 1 |
| Koh, SP | 1 |
| Leadbitter, P | 4 |
| Smithers, F | 1 |
| Tan, ST | 4 |
| Torres, EB | 1 |
| Rotunno, R | 1 |
| Figà-Talamanca, L | 1 |
| Huang, AH | 1 |
| Aggarwal, P | 1 |
| Mahon, M | 1 |
| Cohen, BA | 2 |
| Tognetti, L | 1 |
| Pianigiani, E | 1 |
| Ierardi, F | 1 |
| Cartocci, A | 1 |
| Fiorani, D | 1 |
| de Quattro, M | 1 |
| Caini, M | 1 |
| Cinotti, E | 1 |
| Cevenini, G | 1 |
| Rubegni, P | 1 |
| Gandhi, S | 1 |
| Pandey, MR | 1 |
| Attwood, K | 1 |
| Ji, W | 1 |
| Witkiewicz, AK | 1 |
| Knudsen, ES | 1 |
| Allen, C | 1 |
| Tario, JD | 1 |
| Wallace, PK | 1 |
| Cedeno, CD | 1 |
| Levis, M | 1 |
| Stack, S | 1 |
| Funchain, P | 1 |
| Drabick, JJ | 1 |
| Bucsek, MJ | 1 |
| Puzanov, I | 1 |
| Mohammadpour, H | 1 |
| Repasky, EA | 1 |
| Ernstoff, MS | 1 |
| Galdeano, F | 1 |
| Herón, A | 1 |
| Moreno, S | 1 |
| Aprea, G | 1 |
| Meneses, M | 1 |
| Celik, E | 1 |
| Kaplan, HM | 1 |
| Singirik, E | 1 |
| Frongia, G | 2 |
| Byeon, JO | 2 |
| Mehrabi, A | 2 |
| Günther, P | 2 |
| Yildirimcakar, D | 1 |
| Demirsoy, U | 1 |
| Azizoglu, M | 1 |
| Corapcioglu, F | 1 |
| Giorgio, CMR | 1 |
| Licata, G | 1 |
| Briatico, G | 1 |
| Babino, G | 1 |
| Fulgione, E | 1 |
| Gambardella, A | 1 |
| Alfano, R | 1 |
| Argenziano, G | 1 |
| Saerens, J | 1 |
| De Leye, H | 1 |
| Janmohamed, SR | 4 |
| Li, S | 4 |
| Gao, Q | 1 |
| Lv, R | 2 |
| Xu, G | 2 |
| Li, X | 1 |
| Bi, J | 1 |
| Huo, R | 5 |
| Ji, Y | 4 |
| Yang, K | 2 |
| Zhou, J | 1 |
| Zhang, X | 3 |
| Xiang, B | 3 |
| Jiang, X | 2 |
| Xu, X | 2 |
| Qiu, T | 1 |
| Dai, S | 1 |
| Kong, F | 1 |
| Lu, G | 2 |
| Qiu, Q | 1 |
| Zhang, Y | 2 |
| Nagoba, B | 1 |
| Davane, M | 1 |
| Warad, B | 1 |
| Jamadar, N | 1 |
| Gavkare, AM | 1 |
| Miyazaki, T | 1 |
| Sasai, H | 1 |
| Ohnishi, H | 1 |
| Johansen, ML | 1 |
| Mahendran, G | 1 |
| Lawley, LP | 2 |
| von der Heydt, S | 1 |
| Schwieger-Briel, A | 1 |
| Luchsinger, I | 1 |
| Smith, A | 1 |
| Kernland-Lang, K | 1 |
| Waelchli, R | 1 |
| Neuhaus, K | 2 |
| Kohler, M | 1 |
| Gnannt, R | 1 |
| Schoch, SF | 1 |
| Kurth, S | 1 |
| Farshchian, M | 1 |
| Potts, GA | 1 |
| Braun, M | 1 |
| Metry, D | 1 |
| Antaya, RJ | 2 |
| Mancini, AJ | 2 |
| Kohn, LL | 1 |
| Sugimoto, A | 1 |
| Aoki, R | 1 |
| Toyohara, E | 1 |
| Ogawa, R | 1 |
| Sebaratnam, DF | 1 |
| Rodríguez Bandera, AL | 1 |
| Wong, LF | 1 |
| Wargon, O | 3 |
| McMichael, J | 1 |
| Kurta, AO | 1 |
| Dai, D | 1 |
| Armbrecht, ES | 1 |
| Siegfried, EC | 1 |
| Gesualdo, F | 1 |
| Berti, I | 1 |
| Boccaletti, V | 2 |
| Porcedda, G | 1 |
| Greco, A | 1 |
| Cutrone, M | 2 |
| Dalmonte, P | 2 |
| Kado, M | 1 |
| Shimizu, A | 1 |
| Matsumura, T | 1 |
| Mochizuki, M | 1 |
| Mizuno, H | 1 |
| Hayashi, A | 1 |
| Charny, JW | 1 |
| Moon, AT | 1 |
| Treat, JR | 3 |
| Oberlin, KE | 1 |
| Mahamadou, G | 2 |
| Saka, B | 2 |
| Mouhari-Toure, A | 2 |
| Tchaou, M | 1 |
| Pessinaba, S | 1 |
| Gnassingbé, W | 1 |
| Kombaté, K | 2 |
| Pitché, P | 2 |
| Yazici, N | 1 |
| Sarialioglu, F | 1 |
| Erbay, A | 1 |
| Paul, SP | 1 |
| Boyd, GM | 1 |
| Herwegen, B | 1 |
| Daguzé, J | 1 |
| Saint-Jean, M | 3 |
| Dréno, B | 1 |
| Csoma, ZR | 1 |
| Dalmády, S | 1 |
| Ábrahám, R | 1 |
| Rózsa, T | 1 |
| Rácz, K | 1 |
| Kemény, L | 1 |
| Goss, JA | 1 |
| Konczyk, DJ | 1 |
| Alomari, MH | 1 |
| Maclellan, RA | 1 |
| Greene, AK | 1 |
| De Giorgi, V | 1 |
| Grazzini, M | 1 |
| Benemei, S | 1 |
| Marchionni, N | 1 |
| Botteri, E | 1 |
| Pennacchioli, E | 1 |
| Geppetti, P | 1 |
| Gandini, S | 1 |
| Ginguerra, MA | 1 |
| Saito, O | 1 |
| Fernandes, JBVD | 1 |
| Castro, DS | 1 |
| Matayoshi, S | 1 |
| Tosoni, A | 1 |
| Dalle Carbonare, M | 1 |
| Pettenazzo, A | 1 |
| Perilongo, G | 1 |
| Sartori, S | 1 |
| Rotter, A | 2 |
| de Oliveira, ZNP | 1 |
| Onnis, G | 1 |
| Dreyfus, I | 3 |
| Price, A | 1 |
| Rai, S | 1 |
| Mcleod, RWJ | 1 |
| Birchall, JC | 1 |
| Elhassan, HA | 1 |
| Fogel, I | 1 |
| Ollech, A | 1 |
| Zvulunov, A | 2 |
| Valdman-Greenshpon, Y | 1 |
| Atar Snir, V | 1 |
| Friedland, R | 1 |
| Lapidoth, M | 2 |
| Ben-Amitai, D | 1 |
| Kagami, S | 4 |
| Kaneko, M | 2 |
| Katori, T | 4 |
| Novoa, M | 2 |
| Beltran, S | 2 |
| Giraldo, L | 2 |
| Shahbaz, A | 2 |
| Pardo-Hernandez, H | 2 |
| Arevalo-Rodriguez, I | 2 |
| Lopez, T | 1 |
| Miraglia, E | 1 |
| Schiavetti, A | 1 |
| Varrasso, G | 1 |
| Calvieri, S | 1 |
| Giustini, S | 1 |
| Glover, M | 3 |
| Beattie, PE | 2 |
| Buckley, H | 1 |
| Clark, S | 1 |
| Gach, JE | 1 |
| Giardini, A | 1 |
| Helbling, I | 1 |
| Hewitt, RJ | 1 |
| Laguda, B | 2 |
| Langan, SM | 1 |
| Martinez, AE | 1 |
| Murphy, R | 1 |
| Proudfoot, L | 1 |
| Ravenscroft, J | 1 |
| Shahidullah, H | 3 |
| Shaw, L | 2 |
| Syed, SB | 2 |
| Wells, L | 1 |
| Arnold, R | 1 |
| Hagen, R | 1 |
| Ghareeb, E | 1 |
| Jalali, O | 1 |
| Polites, SF | 1 |
| Rodrigue, BB | 1 |
| Chute, C | 1 |
| Hammill, A | 1 |
| Dasgupta, R | 1 |
| Kishi, A | 1 |
| Chaturvedi, K | 1 |
| Steinberg, JS | 1 |
| Snyder, CS | 1 |
| Xu, W | 1 |
| Yu, F | 1 |
| Yang, X | 3 |
| An, W | 1 |
| Wang, W | 1 |
| Sun, C | 2 |
| McCormick, AA | 1 |
| Tarchichi, T | 1 |
| Azbell, C | 1 |
| Grunwaldt, L | 1 |
| Jabbour, N | 1 |
| Tangtatco, JA | 1 |
| Freedman, C | 1 |
| Phillips, J | 1 |
| Pope, E | 4 |
| O'Brien, KF | 1 |
| Shah, SD | 1 |
| Phillips, RJ | 4 |
| Blei, F | 5 |
| Haggstrom, AN | 1 |
| Perman, MJ | 2 |
| Bellet, JS | 1 |
| Cubiró, X | 1 |
| Poole, J | 1 |
| Martin, JM | 1 |
| Sanchez, S | 1 |
| González, V | 1 |
| Cordero, P | 1 |
| Ramon, D | 1 |
| Sepaskhah, M | 1 |
| Hajizadeh, J | 1 |
| Sari-Aslani, F | 1 |
| Jowkar, F | 1 |
| Babic, V | 1 |
| Schoeffler, A | 1 |
| Moawad, S | 1 |
| Mainard, L | 1 |
| Schmutz, JL | 1 |
| Bursztejn, AC | 2 |
| Subiabre-Ferrer, D | 1 |
| García-Rabasco, A | 1 |
| Correa-González, N | 1 |
| Ortiz-Salvador, JM | 1 |
| Barreda-Solana, M | 1 |
| Babiak-Choroszczak, L | 1 |
| Giżewska-Kacprzak, K | 1 |
| Dawid, G | 1 |
| Gawrych, E | 1 |
| Bagłaj, M | 1 |
| Dakoutrou, M | 1 |
| Alexopoulos, A | 1 |
| Miligkos, M | 1 |
| Georgiadou, E | 1 |
| Kanaka-Gantenbein, C | 1 |
| Kakourou, T | 2 |
| Wu, C | 1 |
| Guo, L | 1 |
| Li, J | 2 |
| Song, D | 1 |
| Feng, L | 1 |
| Düzenli Kar, Y | 1 |
| Özdemir, ZC | 1 |
| Acu, B | 1 |
| Bör, Ö | 1 |
| Cai, R | 1 |
| Moro, R | 1 |
| Fabiano, A | 1 |
| Mangeri, F | 1 |
| Di Buduo, A | 1 |
| Manerba, A | 1 |
| Rossini, M | 1 |
| Calzavara-Pinton, PG | 1 |
| Gualdi, G | 1 |
| Akakpo, AS | 1 |
| Téclessou, JN | 1 |
| Djalogue, L | 1 |
| Gottara, WS | 1 |
| Tchangai-Walla, K | 1 |
| Gumina, ME | 1 |
| Yan, AC | 3 |
| Anger, J | 1 |
| Oliveira, EM | 1 |
| Gabel, J | 1 |
| Reimer, A | 1 |
| Ott, H | 1 |
| Putterman, E | 1 |
| Wan, J | 2 |
| Streicher, JL | 1 |
| Wu, W | 1 |
| Wang, H | 1 |
| Hao, J | 1 |
| Gao, Z | 1 |
| Li, F | 1 |
| Chen, Y | 1 |
| Kao, J | 1 |
| Luu, B | 1 |
| Lee, KC | 1 |
| Bercovitch, L | 1 |
| Craiglow, BG | 1 |
| Reddy, KK | 1 |
| Brauer, JA | 1 |
| Waner, M | 1 |
| Anolik, R | 1 |
| Bernstein, L | 1 |
| Brightman, L | 1 |
| Hale, E | 1 |
| Karen, J | 1 |
| Weiss, E | 1 |
| Geronemus, RG | 1 |
| Xiao, Q | 1 |
| Yu, W | 3 |
| Zhai, YN | 1 |
| Song, HT | 1 |
| Chen, SQ | 2 |
| Zhang, MX | 1 |
| Li, CJ | 2 |
| Xia, Y | 2 |
| Sadykov, RR | 1 |
| Podmelle, F | 1 |
| Sadykov, RA | 1 |
| Kasimova, KR | 1 |
| Metellmann, HR | 1 |
| McGee, P | 1 |
| Miller, S | 1 |
| Black, C | 1 |
| Hoey, S | 2 |
| Maza, A | 1 |
| Caussé, S | 1 |
| Aubert, H | 1 |
| Puzenat, E | 2 |
| Eschard, C | 1 |
| Mahé, E | 1 |
| Miquel, J | 2 |
| Chiaverini, C | 1 |
| Hadj-Rabia, S | 3 |
| Stalder, JF | 2 |
| Ahogo, CK | 1 |
| Ezzedine, K | 3 |
| Prey, S | 1 |
| Colona, V | 1 |
| Diallo, A | 1 |
| Boralevi, F | 2 |
| Taïeb, A | 3 |
| Zheng, JW | 4 |
| Greenberger, S | 1 |
| Bischoff, J | 1 |
| Mendiratta, V | 1 |
| Varghese, B | 1 |
| Chander, R | 1 |
| Parakh, A | 1 |
| Solanki, RS | 1 |
| Luu, M | 1 |
| Block, SL | 1 |
| Blackmon, L | 1 |
| Chandran, S | 1 |
| Ari, D | 1 |
| Jose, J | 1 |
| Niu, JN | 1 |
| Xu, GQ | 1 |
| Lü, RR | 1 |
| Tlougan, BE | 1 |
| Lee, MT | 1 |
| Adams, DM | 1 |
| Shibata, S | 1 |
| Uwajima, Y | 1 |
| Yamada, D | 1 |
| Miyamoto, A | 1 |
| Miyagawa, T | 1 |
| Araki, M | 1 |
| Takahashi, K | 1 |
| Isomura, S | 1 |
| Aozasa, N | 1 |
| Masui, Y | 1 |
| Yamamoto, M | 1 |
| Inuzuka, R | 1 |
| Sato, S | 1 |
| Romanini, MV | 1 |
| Pelegrini, M | 1 |
| Rimini, A | 1 |
| Occella, C | 1 |
| Ferrandiz, L | 1 |
| Toledo-Pastrana, T | 1 |
| Moreno-Ramirez, D | 1 |
| Bardallo-Cruzado, L | 1 |
| Perez-Bertolez, S | 1 |
| Luna-Lagares, S | 1 |
| Rios-Martin, JJ | 1 |
| Frost, G | 1 |
| Relic, J | 1 |
| McSwiney, E | 1 |
| Murray, D | 1 |
| Murphy, M | 1 |
| Novotna, V | 1 |
| Buffon, RB | 2 |
| Theunissen, CI | 1 |
| Smitt, JH | 1 |
| van der Horst, CM | 1 |
| Broeks, IJ | 1 |
| Hermans, DJ | 5 |
| Dassel, AC | 1 |
| van der Vleuten, CJ | 5 |
| van Beynum, IM | 4 |
| Thaivalappil, S | 1 |
| Bauman, N | 1 |
| Saieg, A | 1 |
| Movius, E | 1 |
| Brown, KJ | 1 |
| Preciado, D | 1 |
| Summerer, B | 1 |
| Schneider, J | 1 |
| Boss, EF | 1 |
| Bauman, NM | 2 |
| May, JE | 1 |
| Liew, SH | 3 |
| Malik, MA | 1 |
| Menon, P | 1 |
| Rao, KL | 1 |
| Samujh, R | 1 |
| Patel, NJ | 1 |
| Szychta, P | 1 |
| Stewart, K | 1 |
| Anderson, W | 1 |
| Ye, X | 2 |
| Chen, H | 3 |
| Hu, X | 1 |
| Wang, Z | 1 |
| Li, K | 2 |
| Dong, K | 1 |
| Xiao, X | 1 |
| Zheng, S | 1 |
| Andersen, IG | 1 |
| Rechnitzer, C | 1 |
| Charabi, B | 1 |
| Sagi, L | 1 |
| Ben Amitai, D | 1 |
| El Ezzi, O | 2 |
| Hohlfeld, J | 2 |
| de Buys Roessingh, A | 2 |
| Gonski, K | 1 |
| Bruneau, B | 1 |
| Ábarzúa-Araya, A | 2 |
| Navarrete-Dechent, CP | 1 |
| Heusser, F | 1 |
| Retamal, J | 1 |
| Zegpi-Trueba, MS | 2 |
| Heaton, P | 1 |
| Kennedy, C | 1 |
| Amin, S | 1 |
| Schneider, M | 1 |
| Cremer, HJ | 1 |
| Ruef, P | 1 |
| Chu, DH | 1 |
| Castelo-Soccio, L | 1 |
| Gelfand, JM | 1 |
| Shaddy, RE | 1 |
| Shah, KN | 1 |
| Lokmic, Z | 1 |
| Crock, CM | 3 |
| Penington, A | 1 |
| Bellaud, G | 1 |
| Billon-Grand, NC | 1 |
| Humbert, P | 1 |
| Aubin, F | 1 |
| Song, H | 2 |
| Shi, H | 2 |
| Wang, J | 2 |
| Yu, Y | 1 |
| Chen, W | 1 |
| Zhou, H | 2 |
| Natawidjaja, R | 1 |
| Wang, E | 1 |
| Murabit, A | 1 |
| Gnarra, M | 1 |
| Harper, JI | 1 |
| Tan, CE | 1 |
| Itinteang, T | 3 |
| Marsh, R | 2 |
| Xu, C | 1 |
| Xia, L | 1 |
| Yang, J | 1 |
| Oksiuta, M | 1 |
| Matuszczak, E | 1 |
| Dębek, W | 1 |
| Dzienis-Koronkiewicz, E | 1 |
| Hermanowicz, A | 1 |
| Tylicka, M | 1 |
| Bonifazi, E | 1 |
| Milano, A | 1 |
| Foti, C | 1 |
| Sterker, I | 1 |
| Tegetmeyer, H | 1 |
| Sorge, I | 1 |
| Weißer, M | 1 |
| Böhm, R | 1 |
| Yamamoto, Y | 1 |
| Kounami, S | 1 |
| Okuhira, H | 1 |
| Nakamura, Y | 1 |
| Furukawa, F | 1 |
| Villalba-Moreno, AM | 1 |
| Cotrina-Luque, J | 1 |
| Del Vayo-Benito, CA | 1 |
| Flores-Moreno, S | 1 |
| Bautista-Paloma, FJ | 1 |
| Su, L | 1 |
| Wang, D | 1 |
| Fan, X | 1 |
| Ovadia, SA | 1 |
| Landy, DC | 1 |
| Cohen, ER | 1 |
| Yang, EY | 1 |
| Thaller, SR | 1 |
| Raphael, MF | 4 |
| Breugem, CC | 4 |
| Vlasveld, FA | 2 |
| de Graaf, M | 3 |
| Slieker, MG | 1 |
| Pasmans, SG | 2 |
| Breur, JM | 2 |
| Zhang, M | 1 |
| Guo, Y | 1 |
| Cui, L | 1 |
| Hong, ZJ | 1 |
| Jiang, HQ | 1 |
| Brazzelli, V | 1 |
| Giorgini, C | 1 |
| Barruscotti, S | 1 |
| Codazzi, CA | 1 |
| Mannarino, S | 1 |
| Tzialla, C | 1 |
| Stronati, M | 1 |
| Marseglia, GL | 1 |
| Borroni, G | 1 |
| Porcel Chacón, R | 1 |
| del Boz González, J | 1 |
| Navarro Morón, J | 1 |
| Chen, ZG | 1 |
| Yuan, ML | 1 |
| Zhang, L | 3 |
| Yuan, WE | 1 |
| Aly, MM | 1 |
| Hamza, AF | 1 |
| Abdel Kader, HM | 1 |
| Saafan, HA | 1 |
| Ghazy, MS | 1 |
| Ragab, IA | 1 |
| Korsaga-Somé, N | 1 |
| Abdo, I | 1 |
| Favrais, G | 1 |
| Lorette, G | 2 |
| Rodríguez-Ruiz, M | 1 |
| Tellado, MG | 1 |
| del Pozo Losada, J | 1 |
| Ng, M | 1 |
| Knuth, C | 1 |
| Weisbrod, C | 1 |
| Murthy, A | 1 |
| Jacks, SK | 1 |
| Kertesz, NJ | 1 |
| Witman, PM | 1 |
| Fernandez Faith, E | 1 |
| Bayart, CB | 1 |
| Brandling-Bennett, HA | 2 |
| Ames, JA | 1 |
| Sykes, JM | 1 |
| Lv, D | 1 |
| van Oosterhout, M | 1 |
| de Laat, PC | 2 |
| van Rosmalen, J | 1 |
| Madern, GC | 2 |
| Oranje, AP | 3 |
| Fuijkschot, J | 1 |
| Chow, W | 1 |
| Amaya, CN | 1 |
| Rains, S | 1 |
| Chow, M | 1 |
| Dickerson, EB | 1 |
| Bryan, BA | 1 |
| Moodley, ST | 1 |
| Hudson, DA | 1 |
| Adams, S | 2 |
| Adams, KG | 1 |
| Gong, H | 2 |
| Xu, DP | 3 |
| Li, YX | 1 |
| Cheng, C | 1 |
| Li, G | 2 |
| Wang, XK | 5 |
| Rouhana, HF | 1 |
| Fruge, JH | 1 |
| Massengale, WT | 1 |
| Wedgeworth, E | 1 |
| Irvine, AD | 1 |
| Clayton, TH | 1 |
| Bjerre, JV | 1 |
| Burrows, NP | 1 |
| Foelster-Holst, R | 1 |
| Hedelund, L | 1 |
| Hernandez-Martin, A | 1 |
| Audrain, H | 1 |
| Bhate, K | 1 |
| Brown, SJ | 1 |
| Baryschpolec, S | 1 |
| Darne, S | 1 |
| Durack, A | 1 |
| Dvorakova, V | 1 |
| Gach, J | 1 |
| Goldstraw, N | 1 |
| Goodyear, H | 1 |
| Grabczynska, S | 1 |
| Greenblatt, D | 1 |
| Halpern, J | 1 |
| Hearn, RM | 1 |
| Hughes, B | 1 |
| Jayaraj, R | 1 |
| Johansson, EK | 1 |
| Lam, M | 1 |
| Leech, S | 1 |
| O'Regan, GM | 1 |
| Morrison, D | 1 |
| Porter, W | 1 |
| Ramesh, R | 1 |
| Schill, T | 1 |
| Taylor, AE | 1 |
| Taylor, R | 1 |
| Thomson, J | 1 |
| Tiffin, P | 1 |
| Tsakok, M | 1 |
| McPherson, T | 1 |
| Patrizi, A | 1 |
| Ravenscroft, JC | 1 |
| Svensson, A | 1 |
| Wahlgren, CF | 1 |
| Méchineaud, M | 1 |
| Nicaise, D | 1 |
| Tang, YJ | 1 |
| Zhang, ZZ | 1 |
| Chen, SM | 1 |
| Chen, JW | 1 |
| Yuan, B | 1 |
| Tang, LY | 1 |
| Hing, JW | 1 |
| Tang, JY | 1 |
| Nishikawa, H | 1 |
| Browne, F | 1 |
| Chikermane, A | 1 |
| Parulekar, M | 1 |
| Sulzberger, L | 1 |
| Baillie, R | 1 |
| de Jong, S | 1 |
| Elbert, NJ | 1 |
| Liem, YT | 1 |
| Kon, M | 1 |
| Zaher, H | 1 |
| Rasheed, H | 1 |
| El-Komy, MM | 1 |
| Hegazy, RA | 2 |
| Gawdat, HI | 1 |
| Abdel Halim, DM | 1 |
| Abdel Hay, RM | 1 |
| Mohy, AM | 1 |
| Tong, S | 1 |
| Xue, L | 2 |
| Sun, NN | 1 |
| Ge, J | 1 |
| Zheng, J | 1 |
| Yuan, W | 1 |
| Zhao, H | 1 |
| Techasatian, L | 1 |
| Komwilaisak, P | 1 |
| Panombualert, S | 1 |
| Uppala, R | 1 |
| Jetsrisuparb, C | 1 |
| Zhou, B | 1 |
| Li, W | 1 |
| Shao, RZ | 1 |
| Zhao, DH | 1 |
| Dementieva, N | 1 |
| Jones, S | 1 |
| Shuming, C | 1 |
| Shaoquan, C | 1 |
| Zaizhong, Z | 1 |
| Chengjin, L | 1 |
| Yin, X | 1 |
| Chen, L | 1 |
| Qingjin, H | 1 |
| Lie, W | 1 |
| Liu, ZM | 1 |
| Stringari, G | 1 |
| Barbato, G | 1 |
| Zanzucchi, M | 1 |
| Marchesi, M | 1 |
| Cerasoli, G | 1 |
| Tchana, B | 1 |
| Gritti, A | 1 |
| Lombardi, AA | 1 |
| Carano, N | 1 |
| Sirachainan, N | 1 |
| Lekanan, W | 1 |
| Thammagasorn, Y | 1 |
| Wanitkun, S | 1 |
| Kadegasem, P | 1 |
| Chunharas, A | 1 |
| Castaneda, S | 1 |
| Melendez-Lopez, S | 1 |
| Garcia, E | 1 |
| De la Cruz, H | 1 |
| Sanchez-Palacio, J | 1 |
| Furuta, S | 1 |
| Sato, H | 1 |
| Tsuji, S | 1 |
| Murakami, F | 1 |
| Kitagawa, H | 1 |
| Ren, W | 1 |
| Gao, L | 1 |
| Qiang, C | 1 |
| Zhi, K | 1 |
| Lie, E | 1 |
| Püttgen, K | 1 |
| Lucky, A | 1 |
| Feigenbaum, D | 1 |
| Savva, Y | 1 |
| Holland, K | 1 |
| Drolet, B | 1 |
| Siegel, D | 1 |
| Morel, KD | 1 |
| Yang, L | 1 |
| Yarbrough, KB | 1 |
| Krol, AL | 1 |
| Leitenberger, SL | 1 |
| Mann, JA | 1 |
| MacArthur, CJ | 1 |
| Cheng, CE | 1 |
| Friedlander, SF | 1 |
| Qin, ZP | 2 |
| Fan, XD | 2 |
| Yang, YW | 2 |
| Liu, SH | 2 |
| Zhao, JH | 2 |
| Wang, XY | 2 |
| Zhou, DK | 2 |
| Slaughter, KA | 1 |
| Chen, T | 1 |
| Williams, E | 1 |
| Phillips, JD | 1 |
| Zhang, H | 1 |
| Wei, T | 1 |
| Richter, GT | 1 |
| Jean Wrobel, L | 1 |
| Bod, L | 1 |
| Lengagne, R | 1 |
| Kato, M | 1 |
| Prévost-Blondel, A | 1 |
| Le Gal, FA | 1 |
| Samorano, LP | 1 |
| de Oliveira Labinas, GH | 1 |
| Alvarenga, JG | 1 |
| Rivitti-Machado, MC | 1 |
| Bouer, M | 1 |
| Santos, PC | 1 |
| Silvestre, DA | 1 |
| de Oliveira, ZN | 1 |
| Hartmann, F | 1 |
| Lockmann, A | 1 |
| Grönemeyer, LL | 1 |
| Haenssle, HA | 1 |
| Zutt, M | 2 |
| von Fintel, H | 1 |
| Kühnle, I | 1 |
| Schön, MP | 1 |
| Thoms, KM | 1 |
| Petrovic, J | 1 |
| Trifunovic, B | 1 |
| Vukomanovic, G | 1 |
| Topalovic, M | 1 |
| Trajkovic, G | 1 |
| Parezanović, V | 1 |
| Kutz, A | 1 |
| Rabia, SH | 1 |
| Ilan, EB | 1 |
| Goldberg, I | 1 |
| Harel, A | 1 |
| Spillekom-van Koulil, S | 1 |
| Yu, X | 1 |
| Zhang, J | 2 |
| Liu, M | 1 |
| Chen, R | 1 |
| Gu, Y | 1 |
| Yao, Z | 1 |
| Wang, Y | 1 |
| Yang, Y | 2 |
| Lu, Y | 1 |
| Penington, AJ | 2 |
| Bekhor, PS | 2 |
| Piccolo, V | 1 |
| Moscarella, E | 1 |
| Ametrano, O | 1 |
| Picciocchi, R | 1 |
| Russo, T | 1 |
| Jiang, CH | 1 |
| Lei, SR | 1 |
| Matsuura, T | 1 |
| Kadono, T | 1 |
| Koizumi, H | 1 |
| Kawakami, T | 1 |
| Soma, Y | 1 |
| Fraser, K | 1 |
| Denoyelle, F | 1 |
| Leboulanger, N | 1 |
| Enjolras, O | 1 |
| Harris, R | 1 |
| Roger, G | 1 |
| Garabedian, EN | 1 |
| Sans, V | 1 |
| de la Roque, ED | 1 |
| Berge, J | 1 |
| Grenier, N | 2 |
| Lipsker, D | 1 |
| Dupuis, E | 1 |
| Vergnes, P | 1 |
| Löffler, H | 1 |
| Kosel, C | 1 |
| Cremer, H | 1 |
| Kachel, W | 1 |
| Michel, JL | 1 |
| Patural, H | 1 |
| Naouri, M | 2 |
| Taban, M | 1 |
| Goldberg, RA | 1 |
| Baetz, J | 1 |
| Eigelshoven, S | 1 |
| Marquard, J | 1 |
| Bruch-Gerharz, D | 1 |
| Homey, B | 1 |
| Meissner, T | 1 |
| Benlahrech, S | 1 |
| Ammour, A | 1 |
| Broue, P | 1 |
| Vial, J | 1 |
| Ohanessian, G | 1 |
| Labenne, M | 1 |
| Vabres, P | 2 |
| Rössler, J | 1 |
| Bodemer, C | 1 |
| Schwartz, RA | 1 |
| Sidor, MI | 1 |
| Musumeci, ML | 1 |
| Lin, RL | 1 |
| Micali, G | 1 |
| Rosbe, KW | 2 |
| Suh, KY | 1 |
| Meyer, AK | 2 |
| Maguiness, SM | 1 |
| Holmes, WJM | 1 |
| Gorst, C | 2 |
| Fusilli, G | 1 |
| Merico, G | 1 |
| Gurrado, R | 1 |
| Rosa, T | 1 |
| Acquafredda, A | 1 |
| Cavallo, L | 1 |
| Holmes, WJ | 1 |
| Guldbakke, KK | 1 |
| Rørdam, OM | 1 |
| Huldt-Nystrøm, T | 1 |
| Hanssen, HK | 1 |
| Høivik, F | 1 |
| Schiestl, C | 1 |
| Zoller, S | 1 |
| Subotic, U | 1 |
| Forster-Kuebler, I | 1 |
| Michels, R | 1 |
| Balmer, C | 1 |
| Krause, H | 1 |
| Haß, HJ | 1 |
| Kroker, S | 1 |
| Meyer, F | 1 |
| Halloul, Z | 1 |
| Wagemann, W | 1 |
| Pavlakovic, H | 1 |
| Kietz, S | 1 |
| Lauerer, P | 1 |
| Lakomek, M | 1 |
| Schultze Kool, LJ | 1 |
| van de Kerkhof, PC | 1 |
| Wijnen, MH | 1 |
| Bodak, N | 1 |
| Hamel-Teillac, D | 1 |
| Kupfer-Bessaguet, I | 1 |
| Lacour, JP | 1 |
| Nguyen, JM | 1 |
| Martínez-Escanamé, M | 1 |
| Castillo-Martínez, C | 1 |
| Torres-Álvarez, B | 1 |
| González, FJ | 1 |
| Oros-Valle, C | 1 |
| Moncada, B | 1 |
| Kim, LHC | 1 |
| Hogeling, M | 1 |
| Jiwane, A | 1 |
| Pereyra-Rodríguez, JJ | 1 |
| Mantrana-Bermejo, ME | 1 |
| Fernández-Pineda, I | 1 |
| de Agustín, JC | 1 |
| Conejo-Mir, J | 1 |
| van der Vijver, RJ | 1 |
| Kool, LJ | 1 |
| de Blaauw, I | 1 |
| Schöni, MH | 1 |
| Kernland Lang, K | 1 |
| Sierpina, DI | 1 |
| Chaudhary, HM | 1 |
| Walner, DL | 1 |
| Aljadeff, G | 1 |
| Dubrow, IW | 1 |
| Ghosh, PS | 1 |
| Ghosh, D | 1 |
| Breur, JMPJ | 2 |
| Vos, M | 1 |
| Pasmans, SGMA | 2 |
| Chai, Q | 1 |
| Huang, ZQ | 1 |
| Zhang, DM | 1 |
| Fan, S | 1 |
| Zide, BM | 1 |
| Levine, SM | 1 |
| Sánchez-Carpintero, I | 1 |
| Ruiz-Rodriguez, R | 1 |
| López-Gutiérrez, JC | 1 |
| Goswamy, J | 1 |
| Rothera, MP | 1 |
| Bruce, IA | 1 |
| Mabeta, P | 1 |
| Pepper, MS | 1 |
| Solomon, T | 1 |
| Ninnis, J | 1 |
| Deming, D | 1 |
| Merritt, TA | 1 |
| Hopper, A | 1 |
| Dyme, JL | 1 |
| Thampan, A | 1 |
| Han, EJ | 1 |
| Nyirenda, TL | 1 |
| Kotb, ME | 1 |
| Shin, HT | 1 |
| Lu, J | 1 |
| Qin, G | 1 |
| Huang, J | 1 |
| Zhao, J | 1 |
| Xiang, Y | 1 |
| Zuo, C | 1 |
| Yang, S | 1 |
| Tna, L | 1 |
| Halilbasic, A | 1 |
| Hotic, N | 1 |
| Husaric, E | 1 |
| Rahmanovic, E | 1 |
| Halilbasic, M | 1 |
| Husaric, S | 1 |
| Fischer, CJ | 1 |
| Giannoni, E | 1 |
| Truttmann, AC | 1 |
| Tolsa, JF | 1 |
| Chevallay, M | 1 |
| Seneggen, E | 1 |
| Pauchard, JY | 1 |
| Gehri, M | 1 |
| Hauschild, M | 1 |
| Avagyan, S | 1 |
| Klein, M | 1 |
| Kerkar, N | 1 |
| Demattia, A | 1 |
| Lee, S | 1 |
| Rosenberg, HK | 1 |
| Arnon, R | 1 |
| Thayal, PK | 1 |
| Bhandari, PS | 1 |
| Sarin, YK | 1 |
| Talaat, AA | 1 |
| Elbasiouny, MS | 1 |
| Elgendy, DS | 1 |
| Elwakil, TF | 1 |
| Prashanth, GP | 1 |
| Zhao, Z | 1 |
| de Souza, M | 1 |
| Colli, AM | 1 |
| Chiu, YE | 1 |
| Carcao, M | 1 |
| Fangusaro, J | 1 |
| Kelly, ME | 1 |
| Krol, A | 1 |
| Lofgren, S | 1 |
| Metry, DW | 1 |
| Recht, M | 1 |
| Silverman, RA | 1 |
| Tom, WL | 1 |
| Bingham, MM | 1 |
| Saltzman, B | 1 |
| Vo, NJ | 1 |
| Perkins, JA | 1 |
| Esparza, EM | 1 |
| Deutsch, G | 1 |
| Stanescu, L | 1 |
| Weinberger, E | 1 |
| Sidbury, R | 1 |
| Betlloch-Mas, I | 1 |
| Martínez-Miravete, MT | 1 |
| Lucas-Costa, A | 1 |
| Martin de Lara, AI | 1 |
| Selva-Otalaurruchi, J | 1 |
| Hadaschik, E | 1 |
| Scheiba, N | 1 |
| Engstner, M | 1 |
| Flux, K | 1 |
| Dorresteijn, EM | 1 |
| Jan Danser, AH | 1 |
| Georgountzou, A | 1 |
| Karavitakis, E | 1 |
| Klimentopoulou, A | 1 |
| Xaidara, A | 1 |
| Silva-Valenzuela, S | 1 |
| Navarrete-Dechent, C | 1 |
| Uribe-González, P | 1 |
| Nicklas-Díaz, C | 1 |
| Durr, ML | 1 |
| Huoh, KC | 1 |
| Tan, M | 1 |
| Duan, B | 1 |
| Zhou, CM | 1 |
| Katona, G | 1 |
| Csákányi, Z | 1 |
| Gács, E | 1 |
| Szalai, Z | 1 |
| Ráth, G | 1 |
| Gerlinger, I | 1 |
| Baranowski, S | 1 |
| Winkler, A | 1 |
| Kunzi-Rapp, K | 1 |
| Schaal, M | 1 |
| Hempel, S | 1 |
| Debatin, KM | 1 |
| Posovszky, C | 1 |
| Bauland, CG | 1 |
| Zweegers, J | 1 |
| Dumas de la Roque, E | 1 |
| Nacka, F | 1 |
| Abouelfath, A | 1 |
| Rebola, M | 1 |
| Moore, N | 1 |
| Cloke, A | 1 |
| Lim, LT | 1 |
| Blaikie, A | 1 |
| Kwon, EK | 1 |
| Seefeldt, M | 1 |
| Liu, L | 1 |
| Wang, G | 1 |
| Gao, T | 1 |
| Wolf, R | 1 |
| Shechter, H | 1 |
| Brenner, S | 1 |
| Daniel, RH | 1 |
| Hubler, WR | 1 |
| Wolf, JE | 1 |
| Holder, WR | 1 |
| Dzubow, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sirolimus in the Treatment for Propranolol-resistant Infantile Hepatic Hemangioendothelioma[NCT04406870] | Phase 4 | 36 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study[NCT00967226] | Phase 2 | 19 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to Serious adverse events with prednisolone, primarily temporary growth retardation, <5th percentile.) | ||
| Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma[NCT02342275] | Phase 3 | 377 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma[NCT01072045] | Phase 2 | 50 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double[NCT01056341] | Phase 2/Phase 3 | 512 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| "'' Efficacy of Propranolol in the Treatment of Infantile Hemangioma"[NCT04684667] | Phase 2 | 100 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations[NCT02335242] | Phase 2 | 22 participants (Actual) | Interventional | 2015-05-23 | Completed | ||
| The Efficacy of Timolol 0.5% Gel Forming Solution for the Treatment of Ulcerated Hemangiomas[NCT01408056] | Phase 2 | 0 participants (Actual) | Interventional | 2011-02-28 | Withdrawn (stopped due to Difficulty with recruitment) | ||
| Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study[NCT02012777] | Phase 1 | 9 participants (Actual) | Interventional | 2010-06-30 | Terminated (stopped due to Inability to recruit patients into the study.) | ||
| Role of Propranolol as Compared to Bleomycin in Management of Hemangioma[NCT05327309] | 90 participants (Actual) | Interventional | 2015-05-08 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of allergy/immunology AE per study arm (NCT00967226)
Timeframe: enrollment through study closeout or study withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Allergy/Immunology Events Propranolol | 1 |
| Allergy/Immunology Events Prednisolone | 1 |
Number of constitutional AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Constitutional AEs Propranolol | 2 |
| Constitutional AEs Prednisolone | 3 |
A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available. (NCT00967226)
Timeframe: 4-5 months after initiating therapy
| Intervention | mm squared (Mean) |
|---|---|
| Propranolol | 0.57 |
| Prednisolone | 0.63 |
Number of Dermatologic Adverse Events in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Dermatologic AEs Propranolol | 2 |
| Dermatologic AEs Prednisolone | 1 |
Number of Endocrinologic AEs (of which adrenal crisis does not overlap). (NCT00967226)
Timeframe: enrollment to close out or study withdrawal up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Endocrine AEs Propranolol | 0 |
| Endocrinologic AEs Prednisolone | 7 |
Number of Gastrointestinal AEs in each arm (NCT00967226)
Timeframe: enrollment to study withdrawal or study close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Gastrointestinal AEs Propranolol | 6 |
| Gastrointestinal AEs Prednisolone | 6 |
Number of Growth and Development AEs in each study arm (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Growth/Developoment AEs Propranolol | 0 |
| Growth/Development AEs Prednisolone | 1 |
Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever) (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Infectious AEs Propranolol | 5 |
| Infectious AEs Prednisolone | 3 |
Number of Metabolic or Laboratory AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Metabolic/Laboratory AEs Propranolol | 1 |
| Metabolic/Laboratory AEs Prednisolone | 0 |
Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months
| Intervention | Serious Adverse Events (Number) |
|---|---|
| Number of Serious Adverse Events in Propranolol | 1 |
| Number of Serious Adverse Events in Prednisolone | 11 |
Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm (NCT00967226)
Timeframe: enrollment through study close out or withdrawal, up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Pulmonary/Respiratory AEs Propranolol | 14 |
| Pulmonary/Respiratory AEs Prednisolone | 4 |
Number of Vascular AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months
| Intervention | Adverse Events (Number) |
|---|---|
| Vascular AEs Propranolol | 3 |
| Vascular AEs Prednisolone | 4 |
All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months
| Intervention | Events (Number) | |
|---|---|---|
| Adverse Events | Serious Adverse Events | |
| Overall Number of Adverse Events in Prednisolone | 30 | 11 |
| Overall Number of Adverse Events in Propranolol | 34 | 1 |
The complete healing time of the ulceration was defined as the time from the first dosage of propranolol or atenolol until complete healing of the hemangioma ulceration (assessed up to 6 months). Ulceration is defined as a break in the integrity of the hemangioma surface epithelium (or skin) with or without infection. The information included the extent of ulceration, complications of ulceration, prior duration of ulceration (before treatment), concurrent treatments, and complete healing time. Prior duration of ulceration was defined as the time from the first sign of ulceration until before β-blocker treatment. The complete healing time of the ulceration was defined as the time from the first dosage of propranolol or atenolol until complete healing of the hemangioma ulceration. Concurrent treatments, including oral pain medication, oral antibiotics, topical ointment antibiotics and/or wound dressings, were permitted to treat ulcerated IH and were recorded. (NCT02342275)
Timeframe: from the first dosage of propranolol or atenolol until complete healing ofthe hemangioma ulceration.
| Intervention | weeks (Mean) |
|---|---|
| Propranolol | 4.94 |
| Atenolol | 4.82 |
A complete/nearly complete response at week 96 was considered median-term efficacy. (NCT02342275)
Timeframe: 96 week
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 156 |
| Atenolol | 149 |
Regrowth of more than 20% in hemangioma appearance (including changes in color and/or volume) after stopping the medication was considered significant rebound. The inclusion criteria for rebound analysis were as follows: (1) patients who completed 6 months of treatment and (2) patients who discontinued therapy or were tapering treatment after achieving an any response. The exclusion criteria were as follows: (1) patients who were noncompliant with treatment and (2) patients who did not respond to treatment. Whether a patient had hemangioma rebound was based on the site investigators' assessments after the week 24 treatment. In patients with significant rebound, reinitiation of systemic therapy (either propranolol or atenolol) was recommended. Minor rebound, which was defined as those patients in whose rebound was noted but no reinitiation of systemic therapy or further treatment was necessary, was not included in the analysis. (NCT02342275)
Timeframe: between weeks 24 and 96
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 19 |
| Atenolol | 12 |
"A successful initial response was defined as a HAS score decrease at 1 week after treatment.~A successful initial response was assessed by using HAS in the intention-to-treat population. Previous studies demonstrated that HAS decreases over time after β-blocker treatment, with a dramatic drop occurring in the first week, indicating an immediate therapeutic response. HAS can reflect the rapid effect of β-blocker (either propranolol or atenolol) therapy shortly after initiation." (NCT02342275)
Timeframe: 1 week after treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 171 |
| Atenolol | 163 |
"Changes in IH size and color were classified as a complete response, nearly complete response, partial response or no response. The primary outcome measure was any response at 6 months in the intention-to-treat population of all patients who underwent randomization. The any response included compete, nearly complete and partial responses.~A complete response was defined as no redundant tissue or telangiectasia was identified.~A nearly complete response was defined as a minimal degree of telangiectasis, erythema and skin thickening.~A partial response was defined as a size reduction or change in color that did not meet the nearly complete resolution criteria." (NCT02342275)
Timeframe: 6 month
| Intervention | Participants (Count of Participants) |
|---|---|
| Propranolol | 178 |
| Atenolol | 173 |
"HAS was measured at baseline and at 1, 4, 12, and 24 weeks, including the degree of deep swelling, the color of the hemangioma, and the ulceration assessment:~Assessment of the degree of swelling. It was scored as follows:~6 points if the swelling was tense;~4 points if the swelling was'neutral;~2 points when the swelling was reduced by 50% or more at follow-up; or~0 point when there was no more visible swelling at a follow-up.~Assessment of the color of the IH.~5 points if the hemangioma lesion was bright red all over;~3 points if the hemangioma lesion was matte red or reddish-purple;~1 point if the hemangioma lesion was totally or partially gray;~0 points if the hemangioma lesion was totally or partially skin-colored after involution.~(2) Assessment of the ulceration. -0.5 point for an ulcer ≤1.0 cm2;~One point for an ulcer >1.0 cm2 but <25 cm2;~Two points for an ulcer ≥25 cm2. The HAS score= (Swelling score + color score)/2 +Ulceration score." (NCT02342275)
Timeframe: Baseline and at 1, 4, 12, and 24 weeks
| Intervention | score on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 12 | Week 24 | |
| Atenolol | 4.54 | 3.47 | 2.33 | 1.54 | 0.82 |
| Propranolol | 4.61 | 3.31 | 2.42 | 1.54 | 0.82 |
(NCT01056341)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 8.0 |
| Propranolol 1mg/kg/d 3 Months | 9.8 |
| Propranolol 1 mg/kg/d 6 Months | 37.5 |
| Propranolol 3 mg/kg/d 3 Months | 7.7 |
| Propranolol 3 mg/kg/d 6 Months | 62.8 |
(NCT01056341)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.6 |
| Propranolol 3mg/kg/d 6 Months | 60.4 |
Participants will be followed for the duration of the study, an expected average of 20 weeks. (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | percentage of volume (Mean) |
|---|---|
| Double-Blind Placebo | 5.89 |
| Open-Label Sildenafil | -8.54 |
| Double-blind Sildenafil | -0.642 |
"Subject's evaluation of the overall change in lymphatic malformation. Participants will be followed from baseline to 20 weeks.~Patients rated change as no improvement, minimal improvement (1-25% change), fair improvement (25-50% change), good improvement (50-75% change), and excellent improvement (75-100% change)." (NCT02335242)
Timeframe: Baseline, week 20
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| No improvement | Minimal improvement | Fair improvement | Good improvement | Excellent improvement | |
| Double-Blind Placebo | 1 | 2 | 0 | 2 | 0 |
| Double-Blind Sildenafil | 2 | 4 | 1 | 1 | 0 |
54 reviews available for propranolol and Skin Neoplasms
| Article | Year |
|---|---|
Medical Management of Infantile Hemangiomas: An Update.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin | 2022 |
Infantile Hemangioma: A Current Review.
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Timolol | 2022 |
Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: A meta-analysis of 10 studies.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Combined Modality Therapy; Hemangioma; Humans; | 2022 |
Infantile Hemangiomas.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outcome | 2022 |
[Infantile hemangioma : Clinical manifestation, treatment, and differential diagnoses].
Topics: Child; Diagnosis, Differential; Hemangioma; Hemangioma, Capillary; Humans; Neoplasms, Vascular Tissu | 2023 |
β-blockers in the treatment of periocular infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Ma | 2019 |
Residual Lesions After Pharmacological and Dye-Laser Treatment of Infantile Hemangiomas: Critical Review of 432 Cases.
Topics: Hemangioma, Capillary; Humans; Infant; Lasers, Dye; Observational Studies as Topic; Propranolol; Ski | 2020 |
β-blocker therapy for infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Hemangioma; Humans; | 2020 |
News on infantile haemangioma. Part 2: therapy and evaluation.
Topics: Adrenergic beta-Antagonists; Cost of Illness; Hemangioma, Capillary; Humans; Infant; Laser Therapy; | 2021 |
Infantile hemangioma. Part 2: Management.
Topics: Adrenergic beta-Antagonists; COVID-19; Hemangioma, Capillary; Humans; Infant; Nevus; Pandemics; Prop | 2021 |
Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report.
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow | 2017 |
Infantile hemangioma: pathogenesis and mechanisms of action of propranolol.
Topics: Angiogenesis Inducing Agents; Cell Proliferation; Female; Hemangioma; Humans; Infant, Newborn; Matri | 2017 |
Topical propranolol for infantile haemangiomas: a systematic review.
Topics: Administration, Cutaneous; Antineoplastic Agents; Gels; Hemangioma; Humans; Ointments; Propranolol; | 2018 |
Interventions for infantile haemangiomas of the skin.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Antineoplastic Agents; Bleomycin; Child, Presc | 2018 |
Infantile hemangiomas: what have we learned from propranolol?
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outc | 2018 |
Interventions for infantile haemangiomas of the skin: abridged Cochrane systematic review and GRADE assessments.
Topics: Administration, Cutaneous; Administration, Oral; Adrenergic beta-Antagonists; Bradycardia; GRADE App | 2019 |
[Rare presentations of infantile hemangiomas: 4 cases].
Topics: Biopsy; Buttocks; Delayed Diagnosis; Erythema; Facial Neoplasms; Female; Foot Diseases; Hemangioma, | 2018 |
Role of Magnetic Resonance Image in Children with Lumbosacral and Perineal Hemangiomas: Case Reports and Review of the Literature.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Lipoma; Lumbosacral Region; Male; P | 2019 |
[What's new in pediatric dermatology?]
Topics: Arteriovenous Malformations; Dermatology; Hemangioma; Humans; Pediatrics; Propranolol; Risk Factors; | 2018 |
Can propranolol prevent progression of melanoma?
Topics: Adrenergic beta-Antagonists; Disease Progression; Humans; Melanoma; Neoplasm Recurrence, Local; Prop | 2019 |
Update on infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Male; N | 2013 |
Management of infantile hemangiomas : current and potential pharmacotherapeutic approaches.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aminoquinolines; Hemangioma; | 2013 |
[Infantile hemangioma: update and treatment].
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Early Medical Intervention; Esthetics; Follow- | 2013 |
[What's new about infantile hemangiomas?].
Topics: Hemangioma; Humans; Infant, Newborn; Propranolol; Skin Neoplasms; Skin Ulcer; Vasodilator Agents | 2013 |
Pathogenesis of infantile haemangioma.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Angiopoietins; Embryonic Stem Cells; Endotheli | 2013 |
Haemangioma: clinical course, complications and management.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Cicatrix; Congenita | 2013 |
Use of propanolol for treatment of large infantile haemangiomas-a report of two cases and review of the literature.
Topics: Antineoplastic Agents; Child, Preschool; Facial Neoplasms; Female; Follow-Up Studies; Forearm; Hand; | 2013 |
Multiple cutaneous and hepatic infantile hemangiomas having a successful response to propranolol as monotherapy at neonatal period.
Topics: Adrenergic beta-Antagonists; Disease Management; Female; Hemangioma; Humans; Infant, Newborn; Liver | 2013 |
Propranolol versus corticosteroids: what should be the treatment of choice in infantile hemangiomas?
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Child, Preschool; Cohort Studies; Female; Hemangioma | 2015 |
Propranolol treatment in life-threatening airway hemangiomas: a case series and review of literature.
Topics: Administration, Oral; Airway Obstruction; Biopsy, Needle; Critical Illness; Dose-Response Relationsh | 2013 |
How should propranolol be initiated for infantile hemangiomas: inpatient versus outpatient?
Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based | 2014 |
Diagnosis and management of infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Diagnosis, Differential; Hemangioma; Humans; Infant; Propranolol; Skin | 2014 |
Treatment of complex infantile haemangioma in a resource-poor setting.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Follow- | 2014 |
The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Apoptosis; Catecholamines; Hemangioma; Humans; | 2015 |
Treatment of problematic infantile hemangiomas with propranolol: a series of 40 cases and review of the literature.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; In | 2014 |
[Propranolol therapy for periocular and orbital infantile haemangiomas].
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Newborn; Male; Orbital Neoplasms; P | 2014 |
Local administration of β-blockers for infantile hemangiomas: a systematic review and meta-analysis.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Injec | 2015 |
Beta-blockers for childhood vascular tumors.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Atenolol; Child, Prescho | 2015 |
Current trends in medical management of infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Dermatologic Agents; Early Medical Intervention; Esthetics; Glucocortic | 2015 |
Beta blocker treatment for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Child; Child, Preschool; Dose-Response | 2015 |
Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature.
Topics: Adrenergic beta-Antagonists; Drug-Related Side Effects and Adverse Reactions; Hemangioma; Humans; In | 2016 |
Infantile hemangiomas, complications and treatments.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Airway Obstruction; Drug Therapy, Combination; | 2016 |
Vascular Lesions.
Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Hemangioma; Humans; Plastic Surgery Procedur | 2016 |
LUMBAR syndrome: A case manifesting as cutaneous infantile hemangiomas of the lower extremity, perineum and gluteal region, and a review of published work.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Biopsy; Buttocks; Female; Hemangioma; Humans; | 2017 |
[Efficacy of beta-blockers in infantile capillary haemangiomas: the physiopathological significance and therapeutic consequences].
Topics: Adrenergic beta-Antagonists; Age Factors; Apoptosis; Child; Child, Preschool; Female; Hemangioma, Ca | 2008 |
Infantile haemangiomas: a challenge in paediatric dermatology.
Topics: Adrenergic beta-Antagonists; Cell Proliferation; Hemangioma; Humans; Infant, Newborn; Neovasculariza | 2010 |
[Propanolol used in treatment of infantile hemangioma].
Topics: Adrenergic beta-Antagonists; Eye Neoplasms; Female; Hemangioma; Humans; Infant; Neoplasms, Multiple | 2010 |
[Therapeutic options for haemangiomas of infancy].
Topics: Adrenergic beta-Antagonists; Cryotherapy; Hemangioma; Humans; Infant; Infant, Newborn; Laser Therapy | 2012 |
An infantile bronchial hemangioma unresponsive to propranolol therapy: case report and literature review.
Topics: Adrenergic beta-Antagonists; Beclomethasone; Bronchial Neoplasms; Bronchoscopy; Child, Preschool; Di | 2011 |
Hemangioma update: pearls from 30 years of treatment.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Age Factors; Antibiotics, Antineoplastic; Bleo | 2012 |
Hemangiomas - current therapeutic strategies.
Topics: Angiogenesis Inhibitors; Bleomycin; Child; Cyclophosphamide; Hemangioma; Humans; Interferons; Neovas | 2011 |
[What's new in pediatric dermatology in 2011?].
Topics: Attention; Child; Depression; Dermatologic Agents; Dermatology; Etanercept; Eye Diseases; Humans; Im | 2011 |
Medical management of vascular anomalies.
Topics: Adrenergic beta-Antagonists; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Syndrome; Pr | 2012 |
Infantile hemangiomas: an update.
Topics: Adrenal Cortex Hormones; Biopsy, Needle; Combined Modality Therapy; Dermatologic Surgical Procedures | 2013 |
22 trials available for propranolol and Skin Neoplasms
| Article | Year |
|---|---|
Efficacy and Safety of Propranolol Gel for Infantile Hemangioma: A Randomized, Double-Blind Study.
Topics: Adrenergic beta-Antagonists; Child; Double-Blind Method; Gels; Hemangioma, Capillary; Humans; Infant | 2022 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiopoietin-2; Antifungal Agents; Child; Hemangi | 2022 |
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2021 |
Thirty-two Japanese cases of infantile hemangiomas treated with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Body Image; Female; Follow-Up Studies; Hemangioma | 2018 |
Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cryosurgery; Drug Administration Schedule; Female | 2013 |
The use of propranolol for complicated infantile hemangiomas.
Topics: Administration, Oral; Child, Preschool; Facial Dermatoses; Female; Follow-Up Studies; Hemangioma; Hu | 2013 |
Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas.
Topics: Adrenergic beta-Antagonists; Age Factors; Antineoplastic Agents, Hormonal; Cohort Studies; Female; H | 2013 |
Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Drug Administration Sch | 2013 |
Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study.
Topics: Adrenergic beta-Antagonists; Atenolol; Dose-Response Relationship, Drug; Drug Administration Schedul | 2014 |
Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Therapy, Combination; Female; Follow-Up Stud | 2015 |
Is Propranolol Safe and Effective for Outpatient Use for Infantile Hemangioma? A Prospective Study of 679 Cases From One Center in China.
Topics: Adrenergic beta-Antagonists; Ambulatory Care; China; Female; Follow-Up Studies; Hemangioma, Capillar | 2016 |
Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Hemangioma; Humans; Infant; Male; Pepti | 2016 |
Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions.
Topics: Administration, Oral; Administration, Topical; Antineoplastic Agents; Drug Therapy, Combination; Fac | 2016 |
Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study.
Topics: Administration, Oral; Administration, Topical; Aftercare; Female; Hemangioma; Humans; Infant; Infant | 2016 |
Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Body Height; Body Weight; Child; C | 2016 |
Clinical features and management of multifocal hepatic hemangiomas in children: a retrospective study.
Topics: Administration, Oral; Child, Preschool; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Male; P | 2016 |
Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Facial Neoplasms; Female; Hemangioma; Humans; Inf | 2011 |
[Propranolol in the treatment of problematic infantile hemangiomas].
Topics: Female; Hemangioma; Humans; Infant; Male; Propranolol; Prospective Studies; Skin Neoplasms; Subcutan | 2011 |
Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations.
Topics: Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Follow-Up Studies; Hemangioma; Hu | 2012 |
[The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface].
Topics: Angiogenesis Inhibitors; Combined Modality Therapy; Hemangioma; Humans; Lasers, Solid-State; Propran | 2012 |
Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age.
Topics: Antineoplastic Agents; Cicatrix; Double-Blind Method; Female; Head and Neck Neoplasms; Hemangioma; H | 2013 |
262 other studies available for propranolol and Skin Neoplasms
| Article | Year |
|---|---|
Drug repurposing and rediscovery: Design, synthesis and preliminary biological evaluation of 1-arylamino-3-aryloxypropan-2-ols as anti-melanoma agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Dru | 2020 |
Adverse Drug Reactions Following Propranolol in Infantile Hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Drug-Related Side Effect | 2021 |
A national audit of oral propranolol for the treatment of infantile haemangiomas.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outc | 2022 |
Propranolol response in patients with segmental versus focal facial hemangiomas: A retrospective case-control study.
Topics: Adrenergic beta-Antagonists; Case-Control Studies; Facial Neoplasms; Hemangioma; Humans; Infant; Pro | 2022 |
Significance of the pulsed dye laser in treatment of acral infantile hemangioma.
Topics: Hemangioma; Humans; Infant; Laser Therapy; Lasers, Dye; Propranolol; Skin Neoplasms | 2022 |
Safety assessment of propranolol for infantile hemangioma: a study in an Asian population.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Retrospe | 2022 |
Sequelae following infantile haemangiomas treated with propranolol.
Topics: Administration, Oral; Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Male; Propranolol; | 2021 |
Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2022 |
Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Iatrogenic Disease; Infant; | 2022 |
Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Hemangioma, | 2022 |
Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream.
Topics: Child; Hemangioma; Humans; Hypromellose Derivatives; Infant; Propranolol; Skin; Skin Neoplasms | 2022 |
Does Oral Propranolol Improve the Final Outcome of All Involuted Infantile Hemangiomas? A Matched Retrospective Comparative Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Disease Progression; Hemangioma; Hemangioma, Capi | 2022 |
Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2022 |
Treatment With Oral Propranolol for Refractory Classic Cutaneous Kaposi Sarcoma.
Topics: Administration, Cutaneous; Humans; Propranolol; Sarcoma, Kaposi; Skin; Skin Neoplasms | 2022 |
A premonitory mark of segmental infantile hemangioma.
Topics: Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2022 |
Evaluation of cases with infantile hemangioma requiring treatment.
Topics: Administration, Oral; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Neoplasms | 2022 |
Quality of life improving after propranolol treatment in patients with Infantile Hemangiomas.
Topics: Administration, Oral; Drug-Related Side Effects and Adverse Reactions; Hemangioma, Capillary; Humans | 2022 |
Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Australia; Hemangioma; Hemangioma, Capillary; Hos | 2022 |
Influence of systemic propranolol treatment on the physical development of pediatric patients with infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Hemangioma, Capillary; Humans; Infant; Pro | 2023 |
Severe hypoglycemia in propranolol treatment for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Female; Hemangioma; Hemangioma, Capillary; Humans; Hypoglycemia; | 2022 |
Comprehensive Management of Infantile Hemangiomas Involving the Periorbital Region.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Face; Hemangioma, Capillary; Humans; Infant; Prop | 2022 |
Monitoring oral propranolol for infantile hemangiomata.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Bradycardia; Child; Hemangioma, Capillary; Humans | 2022 |
[Management of ulcers on a segmental hemangioma: A combination of systemic and topical therapies in two pediatric cases].
Topics: Administration, Oral; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Skin Ulcer; Tr | 2022 |
Shikonin reverses pyruvate kinase isoform M2-mediated propranolol resistance in infantile hemangioma through reactive oxygen species-induced autophagic dysfunction.
Topics: Adrenergic beta-Antagonists; Animals; Endothelial Cells; Hemangioma; Propranolol; Pyruvate Kinase; R | 2023 |
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo | 2023 |
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo | 2023 |
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo | 2023 |
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo | 2023 |
Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it?
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Prospective Studies; Skin Neop | 2023 |
Management of infantile hemangiomas-experience of a tertiary hospital.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Male; | 2023 |
Oral Propranolol Used as Adjunct Therapy in Cutaneous Angiosarcoma.
Topics: Combined Modality Therapy; Hemangiosarcoma; Humans; Propranolol; Skin Neoplasms | 2022 |
Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
A study of 95 infantile hemangiomas treated with propranolol: A potentially efficacious combination with laser therapy.
Topics: Administration, Oral; Erythema; Hemangioma; Humans; Infant; Laser Therapy; Propranolol; Skin Neoplas | 2023 |
Indications for surgical resection of complicated infantile hemangiomas in the β-blocker's era: a single-institution experience from a retrospective cohort study.
Topics: Adrenergic beta-Antagonists; Child; Health Facilities; Hemangioma; Humans; Infant; Propranolol; Retr | 2023 |
Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2023 |
Our experience with propranolol for infantile hemangioma.
Topics: Administration, Oral; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outc | 2023 |
Propranolol-induced Involution of Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Ne | 2023 |
Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment.
Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Lasers, Solid-State; Propranolol; Prospective Stu | 2023 |
Factors associated with early relapse of infantile haemangioma in children treated for at least six months with oral propranolol: A case-control study using the 2014-2021 French Ouest DataHub.
Topics: Administration, Oral; Case-Control Studies; Child; Chronic Disease; Hemangioma, Capillary; Humans; I | 2023 |
Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment.
Topics: Child, Preschool; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Retrospective Studies; S | 2023 |
The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Growth and Development; Hemangioma; Hemang | 2023 |
Predictors of poor response to oral propranolol in infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Male; | 2023 |
Practice Variations in Managing Infantile Hemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatme | 2023 |
Intralesional betamethasone versus oral propranolol for localized infantile hemangiomas of the lip.
Topics: Adrenergic beta-Antagonists; Betamethasone; Child; Hemangioma; Humans; Infant; Lip; Propranolol; Pro | 2023 |
Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Drug Overdose; Female; Hemangioma; Hemangi | 2023 |
Symplastic hemangioma developing over an infantile hemangioma during propranolol treatment.
Topics: Female; Hemangioma; Humans; Infant; Neoplasms, Second Primary; Propranolol; Skin Neoplasms; Vasodila | 2019 |
A 7-year follow-up study on untreated deep or mixed facial infantile hemangioma in East-Asian patients: When propranolol was not yet an option.
Topics: Asian People; Cardiovascular Agents; Child; Child, Preschool; Conservative Treatment; Disease Progre | 2019 |
Does treatment with propranolol affect quality of life in infantile hemangioma patients and their parents?
Topics: Child, Preschool; Cohort Studies; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Paren | 2019 |
Beta-blockers exert potent anti-tumor effects in cutaneous and uveal melanoma.
Topics: Adrenergic beta-Antagonists; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Sc | 2019 |
Oral propranolol for the treatment of infantile haemangiomas in Singapore.
Topics: Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Infant, Newborn; Infant, Pre | 2021 |
Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol.
Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchitis; Child, Preschool; Female; Hemangioma; Hu | 2020 |
Special management considerations for propranolol use in breastfed infants of mothers taking antihypertensives.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Breast Feeding; Female; Hemangioma; Humans; In | 2020 |
Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; R | 2020 |
Modalities of use of oral propranolol in proliferative infantile haemangiomas: an international survey among practitioners.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2020 |
Limited utility of repeated vital sign monitoring during initiation of oral propranolol for complicated infantile hemangioma.
Topics: Administration, Oral; Female; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Male; Monitori | 2021 |
Diagnosis and treatment of periorbital infantile hemangiomas: Case series and literature review.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Female; Follow-Up Studi | 2020 |
Enhanced Percutaneous Delivery of Beta-Blockers Using Thermal Resurfacing Drug Delivery System for Topical Treatment of Infantile Hemangiomas.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Drug Delivery Systems; Female; Hemangioma, Cap | 2020 |
Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Retrosp | 2020 |
Retrospective case series of increased oral propranolol dosage for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; R | 2020 |
A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol.
Topics: Hemangioma; Humans; Infant; Infant, Newborn; Neoplasm Recurrence, Local; Propranolol; Skin Neoplasms | 2020 |
Multiple pulmonary infantile hemangiomas responsive to oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant | 2021 |
The impact of propranolol on apoptosis in cutaneous squamous cell carcinomas.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum Cha | 2020 |
Recurrence rate of infantile hemangioma after oral propranolol therapy.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Neoplasm Recurrence, | 2021 |
Evaluation of Clinical Properties and Treatment Responses of Infantile Hemangioma.
Topics: Age Factors; Esthetics; Facial Neoplasms; Female; Glucocorticoids; Hemangioma; Hemorrhage; Humans; I | 2020 |
Comparison between propranolol 2% cream versus timolol 0.5% gel for the treatment of Kaposi sarcoma.
Topics: Adrenergic beta-Antagonists; Humans; Propranolol; Sarcoma, Kaposi; Skin Neoplasms; Timolol | 2021 |
Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas.
Topics: Administration, Oral; Hemangioma; Humans; Infant; Neoplasm Recurrence, Local; Propranolol; Retrospec | 2021 |
Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cohort Studies; Hemangioma; Humans; Infant; Infan | 2021 |
Propranolol for the treatment of ulcerated infantile hemangiomas: A prospective study.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Prospec | 2022 |
Using Topical Citric Acid to Treat an Infected Ulcerated Hemangioma in an Infant: A Case Study.
Topics: Child; Citric Acid; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outcome; Ulce | 2021 |
Propranolol for infantile hemangiomas with hyperinsulinemic hypoglycemia.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Hypogl | 2021 |
Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Retrospe | 2021 |
Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study.
Topics: Adrenergic beta-Antagonists; Cohort Studies; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2021 |
Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Hypertriglyceridemia; Infant; Propranolol; | 2021 |
Persistent dysesthesias in involuted infantile hemangiomas: An uncommon complication in a common condition.
Topics: Administration, Cutaneous; Adolescent; Adult; Child; Child, Preschool; Hemangioma; Hemangioma, Capil | 2021 |
Infantile Hemangiomas Cleared by Combined Therapy With Pulsed Dye Laser and Propranolol.
Topics: Administration, Oral; Cicatrix; Cohort Studies; Combined Modality Therapy; Dose-Response Relationshi | 2021 |
Propranolol for infantile hemangiomas in developing countries.
Topics: Afghanistan; Developing Countries; Facial Neoplasms; Female; Hemangioma; Humans; Infant; Male; Propr | 2017 |
Prescribing propranolol for infantile hemangioma: Assessment of dosing errors.
Topics: Health Care Surveys; Hemangioma, Capillary; Humans; Infant; Medication Errors; Propranolol; Skin Neo | 2017 |
Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience.
Topics: Administration, Oral; Age Factors; Cohort Studies; Dose-Response Relationship, Drug; Drug Administra | 2017 |
Successful Treatment of Infantile Hemangiomas With Propranolol in Low-Birth-Weight Infants.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Low Birth Weight; Infant, Newborn; | 2017 |
Scalp Infantile Hemangioma Complicated by Life-Threatening Bleeding.
Topics: Adrenergic beta-Antagonists; Female; Glucocorticoids; Hemangioma; Hemorrhage; Humans; Infant; Predni | 2017 |
Expanding uses of propranolol in dermatology.
Topics: Administration, Cutaneous; Administration, Oral; Dermatology; Hemangioma; Humans; Practice Patterns, | 2017 |
[Benign neonatal hemangiomatosis: An observation in a child in Togo].
Topics: Female; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Togo; Vasodilator Agents | 2017 |
Use of proporanolol compounding from tablet in infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Chemistry, Pharmaceutical; Drug Compounding; Hemangioma; Humans; Infant | 2017 |
Efficacy and Safety of 2% Topical Propranolol Cream for the Treatment of Proliferating Infantile Strawberry Hemangiomas: Correspondence.
Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Cavernous; Humans; Infant; Propranolol; Skin Ne | 2017 |
Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas.
Topics: Clinical Decision-Making; Cohort Studies; Databases, Factual; Female; Follow-Up Studies; Hemangioma; | 2017 |
Large nose angiosarcoma treated effectively with oral cyclophosphamide combined with propranolol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hemangiosarcoma; Humans; Male; Mid | 2018 |
[Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment].
Topics: Adrenergic beta-Antagonists; Child, Preschool; Follow-Up Studies; Hemangioma; Humans; Hungary; Infan | 2017 |
Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Adult; Child; Child, Preschool; Diagnostic Errors; Female; Hemangioma, | 2017 |
Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study.
Topics: Aged; Cohort Studies; Disease Progression; Disease-Free Survival; Female; Humans; Male; Melanoma; Mi | 2018 |
Clinical and Radiological Evaluation of Periocular Infantile Hemangioma Treated With Oral Propranolol: A Case Series.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Dose-Response Relationship, Dru | 2018 |
Factors associated with delayed referral for infantile hemangioma necessitating propranolol.
Topics: Age of Onset; Clinical Competence; Female; Health Knowledge, Attitudes, Practice; Hemangioma, Capill | 2018 |
Safety profile during initiation of propranolol for treatment of infantile haemangiomas in an ambulatory day-care hospitalization setting.
Topics: Ambulatory Care; Analysis of Variance; Child, Preschool; Cohort Studies; Dose-Response Relationship, | 2018 |
Effectiveness of oral propranolol for infantile hemangiomas started after 5 months of age.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Propranolol; | 2020 |
Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines.
Topics: Administration, Oral; Aortic Coarctation; Clinical Decision-Making; Consensus; Delphi Technique; Der | 2018 |
Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cardiac Imaging Techniques; Cohort Studies; Echoc | 2018 |
Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas.
Topics: Adrenal Cortex Hormones; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Re | 2018 |
Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Lasers, Dye; | 2018 |
Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting.
Topics: Adrenergic beta-Antagonists; Cost of Illness; Cost-Benefit Analysis; Female; Hemangioma; Humans; Inf | 2018 |
Oral propranolol for infantile hemangiomas beyond the proliferative phase.
Topics: Administration, Oral; Asthma; Exanthema Subitum; Female; Hemangioma; Humans; Infant; Male; Photograp | 2018 |
Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Animals; Cell Proliferation; Endothelial Cells; Female; Hemangioma; Hum | 2018 |
Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution.
Topics: Antineoplastic Agents; Combined Modality Therapy; Facial Neoplasms; Female; Hemangioma; Humans; Infa | 2018 |
Surgical treatment outcomes of infantile hemangioma in children: Does prior medical treatment matter.
Topics: Adrenergic beta-Antagonists; Canada; Child; Child, Preschool; Cohort Studies; Female; Glucocorticoid | 2018 |
Late growth of infantile hemangiomas in children >3 years of age: A retrospective study.
Topics: Adrenal Cortex Hormones; Age Factors; Child; Child, Preschool; Cohort Studies; Disease Progression; | 2019 |
Infantile hemangiomas with minimal or arrested growth: A retrospective case series.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Disease Progression; Female; Hemangioma; Human | 2019 |
Tufted angioma arising at the site of hepatitis B vaccination: A case report.
Topics: Adrenergic beta-Antagonists; Female; Glucocorticoids; Hemangioma; Hepatitis B Vaccines; Humans; Infa | 2018 |
Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Child; Heart Rate; Hemangioma; Hu | 2019 |
Atenolol treatment for severe infantile hemangiomas: comparison with a propranolol group of our centre.
Topics: Atenolol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; | 2019 |
Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol.
Topics: Adrenergic beta-Antagonists; Age Factors; Drug Administration Schedule; Female; Hemangioma; Humans; | 2019 |
Progressive infantile hepatic hemangioma not responding to propranolol.
Topics: Adrenergic beta-Antagonists; Age of Onset; Child, Preschool; Disease Progression; Fatal Outcome; Fem | 2019 |
Infantile hemangioma: Efficacy of low-dose propranolol and of intralesional bleomycin injection for propranolol non-response.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Bleomycin; Female; Hemangioma; Humans; Infant; In | 2019 |
Clinical and radiological outcomes of infantile hemangioma treated with oral propranolol: A long-term follow-up study.
Topics: Administration, Oral; Child, Preschool; Disease Progression; Erythema; Female; Follow-Up Studies; He | 2019 |
Objective evaluation of the response of infantile haemangiomas to propranolol treatment using a three-dimensional imaging system.
Topics: Administration, Oral; Feasibility Studies; Female; Follow-Up Studies; Hemangioma; Humans; Imaging, T | 2019 |
[Vascular Cutaneous Abnormalities in Togo: a 120-Case Study].
Topics: Adrenal Cortex Hormones; Child, Preschool; Cohort Studies; Female; Hemangioma; Humans; Infant; Klipp | 2018 |
Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas.
Topics: Administration, Oral; Atenolol; Drug Substitution; Female; Hemangioma, Capillary; Humans; Infant; Pa | 2019 |
EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT.
Topics: Adrenergic beta-Antagonists; Child; Dose-Response Relationship, Drug; Female; Hemangioma; Humans; Pr | 2019 |
[Infantile haemangioma: an update].
Topics: Child; Face; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outcome | 2019 |
Evaluation of a modified outpatient model for using propranolol to treat infantile hemangiomas.
Topics: Ambulatory Care; Blood Glucose; Blood Pressure Determination; Databases, Factual; Dose-Response Rela | 2019 |
Therapeutic efficacy of propranolol for infantile hemangiomas.
Topics: Administration, Oral; Hemangioma; Humans; Infant; Logistic Models; Propranolol; Retrospective Studie | 2019 |
Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser.
Topics: Combined Modality Therapy; Hemangioma; Humans; Infant; Infant, Newborn; Lasers, Dye; Propranolol; Re | 2013 |
Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma, Capillary; | 2013 |
[Effect of propranolol gel on infantile hemangiomas].
Topics: Female; Hemangioma, Capillary; Humans; Hydrogels; Infant; Infant, Newborn; Male; Propranolol; Skin N | 2013 |
Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Face; Female; Hemangioma; Human | 2013 |
Propranolol for infantile haemangioma: a review of current dosing regime in a regional paediatric hospital.
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemangioma | 2013 |
Propranolol-resistant infantile haemangiomas.
Topics: Age of Onset; Antineoplastic Agents; Child, Preschool; Drug Resistance, Neoplasm; Facial Neoplasms; | 2013 |
Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.
Topics: Administration, Oral; Antineoplastic Agents; Child; Child, Preschool; Female; Head and Neck Neoplasm | 2013 |
Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Skin Neoplasms | 2013 |
Successful management of airway hemangioma with propranolol.
Topics: Adrenergic beta-Antagonists; Airway Obstruction; Epiglottis; Female; Head and Neck Neoplasms; Hemang | 2013 |
Treating infantile hemangiomatosis: a case study.
Topics: Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2013 |
[Treatment of superficial infantile hemangiomas with topical propranolol].
Topics: Female; Hemangioma; Humans; Infant; Male; Ointments; Propranolol; Skin Neoplasms; Treatment Outcome | 2013 |
Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Data Collection; Hemangioendothelioma; Hemangioma; H | 2013 |
An update on infantile haemangiomas.
Topics: Antineoplastic Agents; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2013 |
Diffuse neonatal hemangiomatosis with partial response to propranolol.
Topics: Female; Hemangioma; Humans; Infant, Newborn; Liver Neoplasms; Propranolol; Skin Neoplasms; Vasodilat | 2014 |
Dangers of propranolol in preterm infants.
Topics: Apnea; Bradycardia; Hemangioma; Humans; Infant; Infant, Premature; Mouth Neoplasms; Propranolol; Ski | 2013 |
Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure.
Topics: Adrenergic beta-Antagonists; Day Care, Medical; Female; Hemangioma; Humans; Infant; Male; Propranolo | 2014 |
Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Glucose; Blood Pressure; Cardiovascular System; Dose-Response Rel | 2013 |
A new treatment pathway for propranolol use in infantile haemangiomas.
Topics: Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Neoplastic Syndromes, Hereditary; Parents; P | 2014 |
Treatment of infantile hemangiomas with propranolol: clinical guidelines.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Clinical Protocols; Facial Neoplasms; Female; Hemangi | 2014 |
Recurrence of infantile hemangioma after termination of propranolol treatment.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Neoplasm Recurrence, Loc | 2014 |
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Synd | 2014 |
Effectiveness of propanolol for treatment of infantile haemangioma.
Topics: Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Hemangioma; Humans; Infant; Infan | 2014 |
Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.
Topics: Administration, Oral; Dermatologic Agents; Female; Follow-Up Studies; Hemangioma; Hospitals, Univers | 2014 |
Propranolol in infantile haemangioma: simplifying pretreatment monitoring.
Topics: Blood Glucose; Blood Pressure; Drug Monitoring; Echocardiography; Electrocardiography; Facial Neopla | 2014 |
Retrospective follow up of gross motor development in children using propranolol for treatment of infantile haemangioma at Sydney Children's Hospital.
Topics: Adrenergic beta-Antagonists; Child Development; Follow-Up Studies; Hemangioma, Capillary; Hospitals, | 2014 |
Successful treatment of multifocal intracerebral and spinal hemangiomas with propranolol.
Topics: Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; | 2014 |
Severe infantile haemangioma: complications and treatment.
Topics: Adrenergic beta-Antagonists; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Neoplasms | 2014 |
A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas.
Topics: Female; Hemangioma; Humans; Infant; Male; Propranolol; Retrospective Studies; Skin Neoplasms; Treatm | 2014 |
Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study).
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; In | 2014 |
Infantile haemangiomas that failed treatment with propranolol: clinical and histopathological features.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Biomarkers; Female; Hemangioma, Capillary; Humans | 2014 |
PHACE syndrome, a series of six patients: clinical and morphological manifestations, propranolol efficacy, and safety.
Topics: Aortic Coarctation; Child; Child, Preschool; Eye Abnormalities; Facial Neoplasms; Female; Hemangioma | 2015 |
Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Case-Control Studies; Child; Dose-Response Rela | 2015 |
Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Prop | 2014 |
Low-dose propranolol regimen for infantile haemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Administra | 2015 |
Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Follow-Up Studies; Hemangioma; Humans; Infant | 2014 |
Allergic contact dermatitis caused by topical propranolol in a 5-month-old baby.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Dermatitis, Allergic Contact; Female; Hand; | 2014 |
Successful treatment of tufted angioma with propranolol.
Topics: Hemangioma; Humans; Infant; Male; Propranolol; Skin; Skin Neoplasms; Vasodilator Agents | 2014 |
Nadolol for the treatment of infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Child, Preschool; Female; Heart Rate; Hemangioma; Human | 2015 |
Comprehensive therapy for hemangioma presenting with Kasabach-Merritt syndrome in the maxillofacial region.
Topics: Blood Coagulation Tests; Combined Modality Therapy; Embolization, Therapeutic; Female; Follow-Up Stu | 2015 |
Propranolol for infantile haemangiomas: certain chances, potential risks.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol; Skin Neoplasms | 2015 |
Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study.
Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Child, Preschool; Cohort Studies; Drug Monitor | 2015 |
Intralesional injection of diprospan is effective for infantile hemangioma.
Topics: Betamethasone; Drug Combinations; Female; Follow-Up Studies; Glucocorticoids; Head and Neck Neoplasm | 2015 |
Evidence and nuances of propranolol safety.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Female; Heart Rate; Hemangioma; Humans; Male; P | 2015 |
[Infantile hemangiomas: the revolution of beta-blockers].
Topics: Adrenergic beta-Antagonists; Dermatologic Agents; Early Medical Intervention; Esthetics; Follow-Up S | 2014 |
Efficacy of propranolol for cutaneous hemangiomas in premature children.
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemangioma | 2016 |
[Propranolol in infantile hemangiomas].
Topics: Adrenergic beta-Antagonists; Child, Preschool; Facial Neoplasms; Hemangioma; Humans; Propranolol; Sk | 2015 |
Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report.
Topics: Dose-Response Relationship, Drug; Heart Defects, Congenital; Hemangioma; Humans; Infant; Infant, New | 2015 |
A novel topical nano-propranolol for treatment of infantile hemangiomas.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Hydrogels; Infant; | 2015 |
[Kasabach-Merritt phenomenon (KMP) exacerbated by platelet transfusions].
Topics: Aspirin; Axilla; Combined Modality Therapy; Compression Bandages; Disease Progression; Disseminated | 2015 |
[Combination of pulsed dye laser and propranolol in the treatment of ulcerated infantile haemangioma].
Topics: Hemangioma; Humans; Infant; Lasers, Dye; Propranolol; Retrospective Studies; Skin Neoplasms; Treatme | 2016 |
Propranolol Therapy for Problematic Infantile Hemangioma.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Ambulatory Care; Drug Administration Schedule; Fe | 2016 |
Experience with Holter monitoring during propranolol therapy for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Age Factors; Ambulatory Care; Cardiovascular Diseases; Child, Preschool | 2015 |
Scoring the therapeutic effects of oral propranolol for infantile hemangioma: A prospective study comparing the Hemangioma Activity Score (HAS) with the Hemangioma Severity Scale (HSS).
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Cohort Studies; Dose-Response R | 2015 |
Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development.
Topics: Child, Preschool; Cohort Studies; Female; Hemangioma, Capillary; Humans; Infant; Male; Neoplastic Sy | 2015 |
Growth Attenuation of Cutaneous Angiosarcoma With Propranolol-Mediated β-Blockade.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Face; Hem | 2015 |
Shouldn't Propranolol Be Used to Treat All Haemangiomas?
Topics: Female; Hemangioma; Humans; Infant; Male; Propranolol; Retrospective Studies; Skin Neoplasms | 2015 |
Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas.
Topics: Adrenergic beta-Antagonists; Drug Combinations; Hemangioma; Humans; Propranolol; Prospective Studies | 2015 |
Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey.
Topics: Administration, Oral; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hemangioma; H | 2016 |
Haemangioma in an infant whose mother was receiving long-term propranolol treatment during pregnancy.
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol; Skin Neoplasms | 2016 |
Effect of topical propranolol gel on plasma renin, angiotensin II and vascular endothelial growth factor in superficial infantile hemangiomas.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Angiotensin II; Case-Control Studies; Female | 2015 |
Predicting complications with pretreatment testing in infantile haemangioma treated with oral propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Dose-Response Relationship, Dru | 2016 |
Serum levels of renin, angiotensin-converting enzyme and angiotensin II in patients treated by surgical excision, propranolol and captopril for problematic proliferating infantile haemangioma.
Topics: Angiotensin II; Captopril; Cohort Studies; Female; Follow-Up Studies; Hemangioma, Capillary; Humans; | 2016 |
Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Female; Hemangioma; Humans; Infant, Newborn; | 2016 |
Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone.
Topics: Betamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Inj | 2016 |
The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser.
Topics: Administration, Oral; Antineoplastic Agents; Child, Preschool; Combined Modality Therapy; Female; He | 2016 |
[Effects of topical propranolol hydrochloride gel for treatment of infantile hemangioma in nude mice].
Topics: Animals; Gels; Hemangioma; Humans; Immunohistochemistry; Mice; Mice, Nude; Propranolol; Skin Neoplas | 2015 |
Clinical Outcomes of Infants With Periorbital Hemangiomas Treated With Oral Propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Eye; Female; Follow | 2016 |
Propranolol treatment for infantile hemangioma: a case series of sixty-two patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Inf | 2016 |
Response to propranolol in infantile hemangioma.
Topics: Adrenergic beta-Antagonists; Biopsy; Dose-Response Relationship, Drug; Female; Hemangioma; Humans; I | 2016 |
The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol.
Topics: Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Hemangioma; H | 2016 |
Effective treatment for infantile hemangioma with long-pulsed dye laser with oral propranolol medication: a preliminary report.
Topics: Administration, Oral; Combined Modality Therapy; Female; Hemangioma; Humans; Infant; Lasers, Dye; Ma | 2016 |
Low-dose propranolol for infantile hemangioma of the head and neck: Analysis of 23 consecutive patients.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Dose-Response Relationsh | 2017 |
Corticosteroids as an adjunct to propranolol for infantile haemangiomas complicated by recalcitrant ulceration.
Topics: Administration, Oral; Chronic Disease; Drug Therapy, Combination; Glucocorticoids; Hemangioma; Human | 2017 |
Topical Timolol Maleate Treatment of Infantile Hemangiomas.
Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Cohort Studies; Female; | 2016 |
Patient Perspectives: Propranolol for infantile hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Caregivers; Clinical Decision-Making; Female; Hem | 2016 |
Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas?
Topics: Adrenergic beta-Antagonists; Electrocardiography; Hemangioma; Hemangioma, Capillary; Humans; Infant; | 2016 |
[Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Consensus; Female; Hemangioma; Humans; Infant; La | 2016 |
Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas.
Topics: Blotting, Western; Case-Control Studies; Facial Neoplasms; Female; Hemangioma; Humans; Infant; Male; | 2017 |
Propranolol induces a favourable shift of anti-tumor immunity in a murine spontaneous model of melanoma.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Lymphocytes, Tumor-Infiltrating; Melanoma, Exper | 2016 |
Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma, Capillary; Humans; Infant; Male; | 2017 |
Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children.
Topics: Adrenergic beta-Antagonists; Child; Combined Modality Therapy; Female; Hemangioma; Humans; Infant; L | 2017 |
Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment.
Topics: Administration, Oral; Blood Pressure; Drug Dosage Calculations; Electrocardiography, Ambulatory; Fem | 2017 |
Assessment of the effectiveness of topical propranolol 4% gel for infantile hemangiomas.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Age Factors; Child, Preschool; Female; Gels; | 2017 |
Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age.
Topics: Child; Female; Hemangioma; Humans; Male; Mental Disorders; Propranolol; Prospective Studies; Psychol | 2017 |
Efficacy and Safety of 2% Topical Propranolol Cream for the Treatment of Proliferating Infantile Strawberry Hemangiomas.
Topics: Administration, Cutaneous; Female; Hemangioma, Cavernous; Humans; Infant; Infant, Newborn; Male; Pro | 2017 |
Prolonged tumour growth after treatment of infantile haemangioma with propranolol.
Topics: Child; Child, Preschool; Disease Progression; Female; Hemangioma; Humans; Infant; Infant, Newborn; M | 2017 |
Image Gallery: PELVIS syndrome.
Topics: Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Magnetic Resonance Imaging; Meningomyeloc | 2017 |
[Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas].
Topics: Administration, Topical; Adrenergic beta-Antagonists; Asian People; Consensus; Expert Testimony; Hem | 2016 |
Successful propranolol treatment for diffuse neonatal hemangiomatosis.
Topics: Administration, Oral; Female; Hemangioma; Humans; Infant, Newborn; Liver Neoplasms; Magnetic Resonan | 2017 |
67th annual meeting of the American Academy of Dermatology: San Francisco, California, USA, 6-10 March 2009.
Topics: Acne Vulgaris; Dermatology; Hemangioma; Humans; Keratosis, Actinic; Melanoma; Methicillin-Resistant | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
Propranolol for severe infantile hemangiomas: follow-up report.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2009 |
[Propranolol therapy to treat problematic hemangiomas : a new standard therapy makes its debut].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Facial Neoplasms; Female; Follow- | 2009 |
[Response to oral propranolol therapy for ulcerated hemangiomas in infancy].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Forearm; Hemangioma; Humans; Infant; Prop | 2009 |
[Angiomas].
Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Lasers, Dye; Propranolol; Skin Neoplasms | 2009 |
Propranolol for orbital hemangioma.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma, Capillary; Humans; Infant; Magnetic Resonance Imagi | 2010 |
[Infantile hemangioma. Successful treatment with propranolol].
Topics: Female; Hemangioma; Humans; Infant, Newborn; Propranolol; Skin Neoplasms; Treatment Outcome; Vaginal | 2010 |
Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis.
Topics: Adrenal Cortex Hormones; Female; Heart Failure; Hemangioma; Humans; Infant; Liver Neoplasms; Male; P | 2010 |
Propranolol in the management of airway infantile hemangiomas.
Topics: Adrenal Cortex Hormones; Airway Obstruction; Combined Modality Therapy; Drug Therapy, Combination; F | 2010 |
Role of propranolol in the management of periocular hemangiomas.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Eye; Facial Neoplasms; Female; Follo | 2010 |
Propranolol for infantile haemangiomas and neuroglycopenic seizures.
Topics: Adrenergic beta-Antagonists; Blood Glucose; Hemangioma; Humans; Hyperphagia; Hypoglycemia; Infant; L | 2010 |
Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Drug Administration Schedule; Female; Heart Rate; Heman | 2011 |
Hyperkalemia complicating propranolol treatment of an infantile hemangioma.
Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Albuterol; Female; Fluid Therapy; | 2010 |
Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls.
Topics: Adrenergic beta-Antagonists; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Male; Prop | 2011 |
Propranolol for treatment of ulcerated infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Head and Neck Neoplasms; Hemangioma; H | 2011 |
Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function.
Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Follow-Up Studies; Hemangioma; Humans | 2011 |
Diffuse neonatal hemangiomatosis: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Neop | 2012 |
Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo | 2011 |
[Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients].
Topics: Administration, Oral; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Sever | 2011 |
Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment.
Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Disseminated Intravascular Coagulati | 2011 |
[Hemangiomas in childhood].
Topics: Adrenergic beta-Antagonists; Disease Progression; Female; Hemangioma; Hemangioma, Cavernous; Humans; | 2011 |
Infantile intraspinal and extensive cutaneous hemangiomas: excellent response to propranolol.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Female; Hemangioma; Hemangioma, Cavernous, Cen | 2011 |
Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants.
Topics: Adrenergic beta-Antagonists; Biopsy, Needle; Bronchial Hyperreactivity; Cohort Studies; Dose-Respons | 2011 |
[Past, present, and future of propranolol for hemangiomas of infancy].
Topics: Forecasting; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms | 2011 |
Preliminary experiences in treating infantile hemangioma with propranolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Follow-Up S | 2014 |
Atenolol: a promising alternative to propranolol for the treatment of hemangiomas.
Topics: Atenolol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; | 2011 |
[Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Bradycardia; Bronchial Spasm; Clinical Trials | 2011 |
Failure of propranolol in the treatment of childhood haemangiomas of the head and neck.
Topics: Adrenal Cortex Hormones; Airway Obstruction; Anti-Inflammatory Agents; Combined Modality Therapy; Co | 2011 |
Use of propranolol for treatment of hemangiomas in PHACE syndrome.
Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Facial Neoplasms; Female; Hemangioma; Humans; | 2011 |
Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Outpatients; Propranolol; Ret | 2012 |
Initial experiences with propranolol treatment of infantile hemangiomas: report of three cases.
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Propranolol; Skin Neoplasms; | 2011 |
[Pediatrics].
Topics: Adrenergic beta-Agonists; Bacterial Infections; Breast Feeding; Enterocolitis, Necrotizing; Fever; G | 2012 |
Propranolol as a first-line treatment for diffuse infantile hepatic hemangioendothelioma.
Topics: Adrenergic beta-2 Receptor Antagonists; Antineoplastic Agents; Congenital Hypothyroidism; Drug Monit | 2013 |
[Hemangioma. New aspects of pathogenesis, differential diagnosis and therapy].
Topics: Child; Child, Preschool; Cryotherapy; Female; Hemangioma; Humans; Infant, Newborn; Male; Propranolol | 2012 |
Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Antibiotics, Antineoplastic; Bleomycin; Child, Pr | 2012 |
How "unsafe" is propranolol when used in the treatment of infantile hemangioma?
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Skin Neoplasms | 2012 |
Topical propranolol for treatment of superficial infantile hemangiomas.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Oint | 2012 |
Tumor lysis syndrome after propranolol therapy in ulcerative infantile hemangioma: rare complication or incidental finding?
Topics: Antineoplastic Agents; Female; Hemangioma, Capillary; Humans; Hyperkalemia; Hyperphosphatemia; Infan | 2012 |
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioendothelioma; Hemangioma; Humans; Inf | 2012 |
Propranolol reduces infantile hemangioma volume and vessel density.
Topics: Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Skin Neoplasms | 2012 |
Multifocal lymphangioendotheliomatosis with thrombocytopenia: phenotypic variant and course with propranolol, corticosteroids, and aminocaproic acid.
Topics: Aminocaproates; Cerebral Hemorrhage; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Inf | 2012 |
Outpatient treatment of infantile hemangiomas with propranolol: a prospective study.
Topics: Ambulatory Care; Female; Hemangioma, Capillary; Humans; Infant; Male; Propranolol; Prospective Studi | 2012 |
High levels of β2-adrenoceptors are expressed in infantile capillary hemangiomas and may mediate the therapeutic effect of propranolol.
Topics: Adrenergic beta-Antagonists; Female; Gene Expression Regulation; Head and Neck Neoplasms; Hemangioma | 2012 |
Treating hemangioma of infancy with beta-blockers: is there really a risk of hypotension?
Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Skin Neoplasms | 2012 |
Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Photogr | 2012 |
Early growth of infantile hemangiomas: what parents' photographs tell us.
Topics: Adrenal Cortex Hormones; Age Factors; Diseases in Twins; Facial Neoplasms; Female; Hemangioma; Human | 2012 |
Oral propranolol for treating infantile hemangiomas: a case series of 57 patients.
Topics: Administration, Oral; Female; Hemangioma, Capillary; Humans; Infant; Male; Propranolol; Prospective | 2012 |
Airway hemangiomas in PHACE syndrome.
Topics: Aortic Coarctation; Bronchoscopy; Disease-Free Survival; Eye Abnormalities; Female; Follow-Up Studie | 2012 |
Use of propranolol for treatment of infantile haemangiomas in an outpatient setting.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Child; Child, Preschool; Drug Administ | 2012 |
Propranolol for infantile haemangioma: striking effect in the first weeks.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Cohort Studies; Dose-Response Relationship, Drug; | 2012 |
[Infantile hepatic hemangiomas: first-line propranolol monotherapy as new treatment strategy?].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Beckwith-Wiedemann Syndrome; Female; Follow-Up St | 2012 |
Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Hemangioma; | 2013 |
Capillary haemangioma successfully treated with oral beta-blocker in Dar es Salaam, Tanzania: a case report.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Amblyopia; Facial Neoplasms; Female; Hemangioma, | 2013 |
Congenital disseminated tufted angioma.
Topics: Capillaries; Drug Substitution; Female; Glucocorticoids; Hemangioma; Humans; Infant; Prednisone; Pro | 2013 |
Induction of psoriasiform changes in guinea pig skin by propranolol.
Topics: Abscess; Administration, Oral; Alopecia; Animals; Disease Models, Animal; Epidermis; Female; Freund' | 1994 |
Nevus anemicus. Donor-dominant defect.
Topics: Hemangioma; Humans; Male; Middle Aged; Phentolamine; Propranolol; Skin Neoplasms; Skin Transplantati | 1977 |
The interaction between propranolol and epinephrine as observed in patients undergoing Mohs' surgery.
Topics: Analysis of Variance; Blood Pressure; Drug Interactions; Epinephrine; Humans; Propranolol; Prospecti | 1986 |